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Abstract                                                       
 
The advent of high throughput technologies has enabled large-scale measurements of the genome, 
transcriptome, proteome and metabolome of tissues samples, serum and even single cells. 
Additionally, prior biological knowledge is increasingly curated into accessible databases and 
reconstructed into computable models. My research aims to integrate high throughput data and prior 
knowledge to improve disease diagnosis and our understanding of biological systems, by leveraging 
the power of both statistical learning and mechanistic modeling approaches.  
 
The first part of my Ph.D. work is to apply increasingly mechanistic biological constraints in in the 
analysis of high throughput gene expression data to identify molecular signatures of disease 
phenotypes. Chapter 2 discusses the statistical issues and recommended steps to generate accurate and 
reproducible molecular signatures. Chapter 3 presents a new computational method that uses the 
relative expression level of interacting gene pairs as accurate molecular signatures. By incorporating 
prior knowledge about the relations between genes, this method increases molecular signature 
reproducibility compared with previous methods.  
 
Metabolic networks reconstructed from known reaction stoichiometry and gene-protein-reaction 
associations provide a mechanistic context to analyze gene expression data. In Chapter 4, I developed 
a new analysis pipeline that identified perturbations at metabolic branch points (i.e., structures where 
two reactions consume the same metabolite). Different phenotypes (e.g., cancer v.s. normal) can be 
accurately distinguished by transcriptional changes at metabolic branch points. Combining reaction 
expression state (high/low), mass conservation and thermodynamic constraints, I identified additional 
perturbed branch point reaction pairs that are not apparent from expression data alone. 
 
The second part of my PhD work is to contextualize and refine prior knowledge by integration with 
context-specific high throughput data. In Chapter 5, I developed a novel computational method 
mCADRE to reconstruct tissue-specific metabolic models. This method can use transcriptomic, 
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proteomic and metabolomics data to infer the metabolic network of a given tissue or cell type. This 
method can be viewed as using tissue-specific omic data to refine and contextualize prior knowledge 
of metabolism. Using this new method, I reconstructed genome-scale metabolic models for 126 
human tissues, providing a tissue-specific encyclopedia of metabolism. In Chapter 6, I applied 
mCADRE to reconstruct metabolic networks of commonly used breast cancer cell lines. Systematic 
comparison of model prediction and experimental results revealed different types of inconsistencies 
that call for further model curation and the development of new modeling approaches. 
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Chapter 1. Introduction and Overview                                
 
Decades of molecular and cellular biology research have generated enormous knowledge about how 
biological systems work from molecular to physiological levels. Such prior knowledge is increasingly 
curated in easily accessible databases [1, 2]. On the other hand, the advent of high throughput 
molecular profiling technologies, most notably gene expression microarrays [3], enable the 
comprehensive measurement of a large number of molecular entities simultaneously. Capitalizing on 
advances in various “omics” technologies, large community projects such as The Cancer Genome 
Atlas (TCGA) have generated enormous amounts of data that characterize hundreds of diverse tumor 
samples with the genome sequence, epigenetic changes (methylation), gene expression and DNA 
copy number [4-9]. Similar efforts have been devoted to commonly used cancer cell lines [10-12]. 
The key challenge is to gain novel information from both prior knowledge and a large amount of omic 
data that can aid disease diagnosis and improve our understanding of biological systems.  
 
Herein, I present new computational tools and methodologies I developed that aim to combine prior 
knowledge with high throughput data to guide disease diagnosis and generate new hypotheses. The 
development of these tools uses both statistical learning approaches and mechanistic modeling. The 
goal of this chapter is to provide a high-level introduction to both approaches and an overview of 
chapters in the thesis.   
 
1.1 Learning Disease Molecular Signatures from High Throughput Data 
 
A molecular signature is defined as “a set of biomolecular features (e.g. DNA sequence, DNA copy 
number, RNA, protein, and metabolite expression) together with a predefined computational 
procedure that applies those features to predict a phenotype of clinical interest on a previously unseen 
patient sample” [13]. In the most typically case of transcriptomics, the mRNA level of p genes are 
measured in n labeled samples (binary: disease/ normal or continuous: survival time). The aim is to 
use various statistical approaches to construct a computational model consisting of a subset of 
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informative genes that accurately predict the defined endpoint. Molecular signatures have been 
developed for disease diagnosis (e.g., disease v.s. normal), prognosis (e.g., long v.s. short survival), 
and treatment selection (e.g., responsive v.s. resistant). Molecular signatures derived from gene 
expression profiling such on MammaPrint [14] and Oncotype DX [15] have been used in clinic to 
assess risk of breast cancer metastasis and recurrence.  
 
During the past decade, numerous tools have been developed to derive molecular signatures from 
(mainly) gene expression data. Initially, standard statistical and machine learning approaches were 
applied to gene expression data. This includes using statistical tests (t-test or Wilcoxon test) to 
identify differentially expressed genes (DEGs) between two conditions, or use general-purpose 
classification methods such as Support Vector Machines (SVM) and k-nearest neighbors (kNN) to 
classify samples. Tools specifically tuned for the “large p, small n situation” in gene expression data 
analysis, such as Significant Analysis of Microarrays (SAM)[16] and Prediction Analysis of 
Microarrays (PAM)[17] were developed. These methods often ignore the dependence structure 
between genes.   
 
Newer methods increasingly aim to put more biological constraints on gene expression data analysis, 
beginning with methods that aim to identify biologically meaningful gene sets that show coordinated 
expression changes between conditions. Gene Set Enrichment Analysis (GSEA) [18] is the most 
popular approach among them. The aim of GSEA is to determine whether members of a pre-defined 
gene set S (biological pathways) tend to occur toward the top (or bottom) of the list L of differentially 
expressed genes. GSEA ignores the connections between genes in biological pathways. Later on, 
methods that account for biological pathway structure, such as impact factor (IF) analysis [19] were 
developed. To extend analysis beyond existing pathways, which only cover a small fraction of 
well-studied human genes, Chuang et al [20] developed a method that identify modules enriched with 
differentially expressed genes in a protein-protein interaction network to classify breast cancer 
patients. Therefore, the field of molecular signature discovery has been evolving from single genes, to 
a priori defined gene sets, to network-based diagnostic signatures.  
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1.2 Genome-Scale Models of Metabolism 
 
Metabolism is fundamental to all cellular processes. Intermediates in metabolism are intimately linked 
to cellular signaling: ATP is the substrate for phosphorylation in kinase cascades; acetyl-CoA is the 
substrate of acetylation of histones that alter chromatin dynamics; S-adenosyl methionine provides 
substrate for DNA methylation. On the other hand, metabolism is under extensive control of cellular 
signaling, with PI3K/Akt/mTOR pathway being the most prominent regulator. Perturbations in 
metabolism are found in most human disease such as inborn errors of metabolism, cancer, diabetes 
and obesity, and neurodegenerative diseases.   
 
Metabolic networks are among the best studied biological networks, thanks to decades of detailed 
biochemical experiments. Such prior knowledge is systematically curated into computable 
genome-scale metabolic models (e.g., Recon 1 [21] and Recon2 [22]). The latest human metabolic 
network, Recon 2, includes over 7000 metabolic reactions, 2600 metabolites, and 1700 metabolic 
genes[22]. The content of a metabolic network can be divided into two parts. The most basic part is 
the stoichiometric matrix, where rows represent metabolites, columns represent reactions, and 
numeric entries (i, j) represent the stoichiometric coefficient of metabolite i in reaction j. The other 
part is the gene-reaction rules, which describe what genes encode what proteins and how these 
proteins are organized to catalyze reactions (isozymes or enzyme complexes). Various constraints can 
be applied to the metabolic network to reduce the number of possible metabolic states under a 
particular condition. Typical constraints include mass balance, thermodynamic constraints, nutrient 
uptake rates, expression of metabolic genes (e.g., penalize flux through reactions catalyzed by 
lowly-expressed enzymes). The reconstruction and simulation of genome-scale metabolic networks 
are well-established processes and there are many computational tools to explore the capabilities of 
metabolic models [23].  
 
There are numerous different types of human tissues (e.g., liver, lung, breast) and cell types (e.g., 
Myocytes, adipocytes, hepatocytes). Different tissues express different sets of metabolic genes and 
carry out a different subset of all metabolic capabilities encoded in the genome: gluconeogenesis and 
urea cycle occurs exclusively in the liver, while lipid synthesis and transport genes are highly 
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enriched in adipose tissues. A few computational methods have been developed to account for such 
tissue-specificity in metabolism [24-26].  
 
One important application of tissue-specific metabolic models is to study metabolic aberrations in 
cancer and identify selective metabolic targets. Metabolic reprogramming to fuel proliferation is a 
hallmark of cancer. Well-known oncogenes and tumor suppressor genes regulate different aspects of 
metabolism[27]. Mutations in metabolic genes (e.g., SDH, FH, IDH) are also causally involved in 
tumorigenesis [28]. Common metabolic aberrations shared by most types of cancer are increased 
glucose uptake, increased lactate secretion and greater tendency to use glutamine. However, 
depending on tissue context and underlying genetic lesion, cancer tissues can also have prominent 
metabolic differences [29]. This heterogeneity is also reflected at the transcriptomic level: while 
upregulation of nucleotide biosynthesis and glycolysis are frequently observed across tumors, 
expression changes of other pathways (e.g., oxidative phosphorylation) are very heterogeneous [30]. 
Therefore, it is not only important to develop metabolic models that represent the common features of 
all cancer types, but also cancer type specific metabolic models that represent the unique metabolic 
capabilities of tumors with different tissues types and genetic lesions. Such tissue-specific metabolic 
models have been used to identify metabolic targets that selectively affect cancer proliferation. In 
particular, using metabolic modeling, it was identified that haeme oxygenase is synthetically lethal 
with FH, which is frequently mutated in renal carcinoma. Therefore, targeting FH would only affect 
RCC with mutant FH but spare normal cell with wild type FH [31]. As genome sequencing continues 
to identify both copy number loss and putative damaging mutations in metabolic genes, using 
genome-scale metabolic models to systematically identify synthetic lethal partners of cancer-specific 
metabolic mutations might be a promising path to selective drug targets.     
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1.3 Dissertation Organization 
 
Chapter 1 introduces the central themes and topics for the work described in subsequent chapters. 
Chapter 2 systematically reviews challenges and consensus in generating molecular signatures from 
omic data.  
Chapter 3 describes a new computational method that combines prior information on protein-protein 
interaction with gene expression data to identify biologically interpretable interactions that accurately 
classify clinically relevant disease phenotypes. This is a statistical modeling approach built upon an 
existing family of methods called Relative Expression Analysis.  
Chapter 4 describes a new computational tool (metabolic Context Assessed by Deterministic 
Reaction Evaluation, mCADRE) to reconstruct tissue-specific genome-scale metabolic networks 
based on prior biochemical knowledge and tissue-specific transcriptomic, proteomic and metabolomic 
data.  
Chapter 5 describes the application of mCADRE to build genome-scale metabolic models of 
commonly used breast cancer cell lines and the analysis of various functional genomic data using the 
cell line specific metabolic models.  
 
Chapter 6 describes the analysis of transcriptomic data in a metabolic network context, which 
considers both network topology and function. 
 
Chapter 7 summarizes the dissertation and provides perspectives on future developments.  
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Chapter 2. Molecular signatures from omics data: from chaos to consensus 
 
2.1 Introduction 
 
In recent years, new high-throughput measurement technologies for biomolecules such as DNA, 
RNA, and proteins have enabled unprecedented views of biological systems at the molecular level. 
The fields of research associated with obtaining and understanding such measurements – for instance, 
genomics, transcriptomics, and proteomics – are sometimes referred to in aggregate as omics. Given 
molecular measurements taken from a biological system, a natural goal is to develop a statistical 
model that uses these measurements to predict a clinical outcome of interest, such as disease status, 
survival time, or response to therapy. In this article, we will discuss the process of using omics data to 
discover a molecular signature. Here we define a molecular signature as a set of biomolecular 
features (e.g. DNA sequence, DNA copy number, RNA, protein, and metabolite expression) together 
with a predefined computational procedure that applies those features to predict a phenotype of 
clinical interest on a previously unseen patient sample. A signature can be based on a single data type 
[3, 32-34] or on multiple data types [35-38]. The overall process of identifying molecular signatures 
from various omics data types for a number of clinical applications is summarized in Figure 2.1. 
 
 
Many possible clinical phenotypes might be predicted by a molecular signature; a few examples 
include prediction of disease risk and progression [39-41], response to therapeutic drugs [42-44] and 
their physiological toxicity [45, 46], and time to disease recurrence or death [47, 48]. (Note that in this 
review, the molecular signatures that we consider may be effect modifiers or may only be of 
prognostic value; in either case, we refer to the molecular signature as “predicting” a clinical 
phenotype of interest.) A successful case of the clinical utility of omics-derived molecular signatures 
is MammaPrint [14], a diagnostic test approved by the Food and Drug Administration for clinical use. 
MammaPrint is a 70-gene expression signature used to predict breast cancer prognosis and to 
determine the appropriate therapeutic regimen for lymph node negative breast cancer patients with 
either ER positive or negative. The list of 70 genes was selected based on correlation with clinical 
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outcome (distant metastasis vs. no metastasis), and underwent successful validations on independent 
patient cohorts [49, 50]. 
 
Despite a few notable exceptions such as MammaPrint, the successful discovery of molecular 
signatures has largely been hampered by limited reproducibility and variable performance on 
independent test sets [51-57], as well as difficulty in identifying signatures that outperform standard 
clinical measurements like the cardiovascular disease risk C-reactive protein (CRP) [58]. These 
difficulties can be attributed in large part to the low signal-to-noise ratio inherent to omics datasets, 
the prevalence of batch effects in omics data, and molecular heterogeneity between samples and 
within populations [59]. These issues are exacerbated by the fact that the datasets used to develop 
molecular signatures tend to have small sample sizes relative to the number of molecular 
measurements [60]. Moreover, improper study design, inconsistent experimental techniques, and 
flawed data analysis can lead to further challenges in the process of molecular signature discovery. 
Though there has been marked progress in the field of molecular signature discovery in recent years, 
there remains a clear need for further improvements in the discovery process in order for omics-based 
technologies to begin to achieve their full clinical potential. 
 
 
2.2 The four stages of molecular signature discovery 
 
Roughly speaking, the process of molecular signature discovery on the basis of omics data consists of 
four major stages: 
 
1. Defining the scientific and clinical context for the molecular signature.  
2. Procuring the data.  
3. Performing feature selection and model building.  
4. Evaluating the molecular signature on independent data sets.  
 
In the sections that follow, we will discuss each of these stages in turn. 
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Stage 1: Defining the scientific and clinical context 
 
Before embarking on the process of molecular signature discovery, one must first identify a specific 
scientific and clinical context for the molecular signature. A molecular signature uses omics 
measurements to predict a clinical phenotype of interest; therefore, it is natural that before 
constructing such a signature, one must first determine what type of omics measurements will be 
used, and what clinical phenotype will be predicted.  
 
We first consider the problem of selecting a suitable omics data type for a molecular signature. A 
signature intended to distinguish between cancer and normal tissue could be based upon a number of 
omics data types; for instance, one might base the signature upon gene expression measurements, if it 
is believed that this type of cancer shows altered expression of some genes relative to normal tissue, 
or upon DNA sequence data, if samples from this cancer are characterized by particular mutations or 
copy number changes. However, given a clinical phenotype of interest, certain types of omics data 
might not form the basis for a sensible molecular signature. For instance, it would not be reasonable to 
attempt to create a molecular signature to screen for adult onset (type II) diabetes on the basis of DNA 
sequence data alone because an individual’s DNA sequence remains essentially static throughout his 
or her lifetime, but risk of developing the disease may change.  
 
We now consider the clinical context of the molecular signature. A gene expression-based signature 
that can distinguish between cancer and normal tissues would be of little practical use if a physician 
can easily make the same distinction using standard (and less expensive) clinical approaches. 
Similarly, a signature that can distinguish between two subtypes of cancer is useful only if those two 
subtypes differ in some clinically relevant way, such as in survival time or response to therapy, since 
otherwise the information about cancer subtype provided by the molecular signature may not serve a 
practical purpose. As an example, gastrointestinal stromal tumors (GISTs) and leiomyosarcomas 
(LMSs) are remarkably similar morphologically and were originally classified as being the same 
cancer. However, it was found that they respond very differently to distinct therapies, and thus a 
signature that can distinguish between these two diseases based on gene expression in tissue samples 
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can be useful [34]. An example outside of cancer involves the use of metabolomic information from 
human serum to noninvasively diagnose and monitor Alzheimer’s Disease (AD) progression [61-63].  
 
Stage 2: Data procurement 
 
The development of a molecular signature requires the availability of adequate omics data for which 
the clinical phenotype of interest is available. In general, there are two ways in which such data can be 
procured: new data can be collected experimentally for the specific purpose of molecular signature 
discovery, or else existing data (collected previously for other purposes, and generally publicly 
available) can be used. There are pros and cons of either approach. Collecting new data has a major 
advantage, in that all aspects of the experiment can be carefully controlled. On the other hand, data 
collection is expensive, and given the large sample sizes necessary for successful molecular signature 
discovery, using existing data sets may be a more feasible approach. There are a number of public 
data repositories from which omics data and associated clinical phenotypes can be obtained. For 
instance, a useful source of gene expression data is NCBI Gene Expression Omnibus (GEO), a 
repository of over twenty six thousand studies that continues to grow at a rapid pace. Other public 
data repositories include ArrayExpress [64] and Sequence Read Archive [65]. Regardless of how the 
data are procured, it is crucial that the samples correspond to the scientific and clinical context of 
interest, as described in the previous section.  
 
In order for a data set to be suitable for molecular signature discovery, the samples must be collected 
under appropriate experimental and analytical conditions. As an example, any biological factors (such 
as gender, age, or ethnicity) that may be associated with the clinical phenotype of interest or with the 
omics measurements should be taken into consideration in the process of data procurement. In 
addition, to reduce the prevalence of batch effects, factors such as sample collection and processing 
procedures, laboratory personnel, study run-dates, reagent sources, measurement instruments, and 
data processing methods should be carefully controlled [66-68]. Deviations in these protocols can 
have a surprisingly large effect on the omics measurements obtained, often larger than the effect of 
the clinical phenotype of interest [69]. Ideally, there should be no association between the clinical 
phenotype of interest and these factors. For instance, in the case of a molecular signature that 
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classifies tissue samples into tumor versus normal, there should be no difference between the tumor 
and normal samples in terms of the laboratory personnel who performed the sample preparation, or 
the sample run-dates. If experimental and analytical procedures are not carefully controlled, they can 
result in confounding with the clinical phenotype of interest, leading to the development of a classifier 
that performs very well on the data used in its development, but that will perform poorly on 
independent test samples. 
 
To the extent that analytical and experimental factors do vary among the samples, these factors should 
be explicitly included in the model used to develop the classifier. Normalization procedures have been 
proposed that are intended to reduce the effect of measured and unmeasured external factors on omics 
data [70]; however, good experimental design remains the best strategy [71]. Exploratory data 
analysis techniques, such as hierarchical clustering (Fig. 2.2A) and principal components analysis 
(Fig. 2.2B) can be useful tools to assess the extent to which covariates that are not of primary interest 
may have affected the data. 
 
When existing data is used for omics-based molecular signature discovery, it is particularly important 
that sufficient information about the experiment is available to ensure that good experimental design 
was followed (this will be discussed further in Section 4). For instance, if the run date for each sample 
is not given, then one cannot be certain that the clinical phenotype of interest is not highly confounded 
with run date. 
 
Unfortunately, many omics studies have sample sizes substantially smaller than would be required for 
the successful identification of molecular signatures. A molecular signature that is developed on the 
basis of a small number of samples is more likely to be sensitive to technical and biological sources of 
noise and variation, and less likely to capture the aspects of the data that are truly associated with the 
phenotype of interest. This exacerbates the risk of over-fitting, wherein the signature performs well on 
the samples used for signature development but fails to correctly predict the clinical phenotype of 
interest in previously unseen samples. In contrast, global molecular characteristics of a particular 
phenotype may become more apparent as sample size increases. Therefore, having a large sample 
size, while by no means a cure-all, will greatly improve the odds that a given attempt at molecular 
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signature discovery will prove fruitful.   Integrating across multiple datasets of the same phenotypes 
from different labs can also help to amplify the primary biological signal of interest relative to noise.  
Of course, whether a given sample size is “large” or “small” depends the type of omics data being 
used for signature discovery, the clinical phenotype of interest, and many other factors.  
 
Stage 3: Feature selection and model building 
 
Once a scientific and clinical context has been established and one or more data sets have been 
identified, we can develop a molecular signature through (1) feature selection; and (2) model building. 
These two tasks can be performed together or separately. 
 
We first consider the task of feature selection. A typical omics experiment simultaneously measures 
thousands or even millions of biological features (e.g. single nucleotide polymorphisms, RNA 
transcripts, protein levels) on each patient sample. However, just because thousands of molecular 
measurements are obtained does not mean that thousands of molecular measurements should be used 
in the molecular signature. Since financial cost, technical practicality, and measurement robustness 
are important criteria to select signatures, then if all else is equal, a signature that could be ultimately 
measured via PCR or Western blot is favored over a signature that requires a technique involving 
many more protocol steps, such as in omics measurements. In order to reduce the number of features 
used in molecular signature development, feature selection is performed. Feature selection can be 
performed in a supervised manner (e.g. the 20% of features that are most associated with the clinical 
phenotype of interest are selected), or in an unsupervised manner (e.g. the 20% of features with the 
highest variance are selected). Once a set of features has been selected, only those features are used in 
the model building process, which is described next.  
 
We now consider the task of model building – that is, the process of developing a specific 
computational procedure that can be applied to the omics measurements from a future patient sample 
in order to predict the unknown clinical phenotype of interest for that sample. There are many 
possible approaches to building such a model, and in particular, the type of model used will depend on 
the clinical phenotype of interest. For instance, if we wish to develop a molecular signature to predict 
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time to cancer recurrence, then a Cox proportional hazards model might be appropriate. On the other 
hand, to develop a molecular signature that can distinguish between cancer and normal tissue, one 
could use a classification approach, such as logistic regression, support vector machines, neural 
networks, or linear discriminant analysis. Some approaches for model-building involve first 
performing an unsupervised technique, such as clustering or principal components analysis, followed 
by a supervised procedure, such as logistic regression.  
 
It is worth noting that it is not always obvious what type of model should be used in a given setting. 
For instance, suppose that we wish to develop an expression-based signature in order to distinguish 
between tumor and normal samples. It sounds easy enough. An obvious approach is to develop a 
binary classifier, using e.g. logistic regression, which assumes that there is a linear boundary 
separating the two classes (tumor and normal). However, in some settings, this assumption might not 
be appropriate. For instance, maybe the normal samples do not belong to a single homogeneous group: 
there may be differences among the normal patients that are at least as great as the differences 
between tumor and normal patients. Alternatively, perhaps the tumor samples are heterogeneous 
because there are in fact several distinct subtypes of the tumor. In such a setting, a binary treatment of 
the problem that assumes a linear decision boundary may be inappropriate. Therefore, it is important 
to choose a model that is well-suited for the scientific and clinical contexts. 
 
Once we have developed a model, how can we determine whether it is any good? Despite certain 
drawbacks [72, 73], the most popular approach for evaluating model performance in this context is 
cross-validation. (Cross-validation is also often used for tuning parameter selection, though that 
application is outside of the scope of this article.) Cross-validation involves repeatedly splitting the 
samples in the data set into training and test sets, performing all aspects of feature selection and model 
building on the training set, and evaluating the model’s performance on the test set. Cross-validation 
can also be used to select from among a small number of possible models: the model with the smallest 
cross-validation error rate should be chosen. 
 
Cross-validation is a simple and intuitive approach to estimating the error rate associated with a 
model, but it must be performed with care. Most importantly, within each cross-validation fold, no 
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information about the test set can be used in building the model on the training set. For instance, 
suppose that one performs feature selection by selecting the 10% of features whose t-statistics 
between cases and controls are largest. One then performs logistic regression, using only these 
features, to develop a classifier to distinguish between cases and controls. How should the 
cross-validation error rate be calculated? Consider the following two approaches: 
 
Approach 1 (incorrect) 
Identify the 10% of features that differ most between cases and controls, and use only those 
features henceforth. Perform cross-validation by repeatedly splitting the samples into training 
and test sets, fitting a logistic regression model on the training set (using just the 10% of 
features previously identified), and then evaluating the model’s performance on the test set. 
 
Approach 2 (correct) 
Perform cross-validation by repeatedly splitting the samples into a training set and a test set. 
Within each training set, identify the 10% of features that differ most between cases and 
controls, and use those features to fit a logistic regression model. Then evaluate the 
performance of this model on the test set. 
 
The difference may seem subtle, but it is in fact crucial. Approach 1 will yield a woeful underestimate 
of the true error rate, because the 10% of features that differ most between cases and controls were 
identified using all of the samples, including those in the test set, rather than simply the training 
samples. In effect, if Approach 1 for cross-validation is taken, then perfect error rates can potentially 
be obtained even on data sets in which the “case” and “control” labels were assigned randomly! On 
the other hand, in Approach 2, feature selection is performed using the training set within each cross 
validation fold, and so the resulting cross-validation error rate is valid. Unfortunately, the difference 
between Approaches 1 and 2 is often overlooked, and the literature is rife with papers in which 
extraordinarily low, but grossly inaccurate, cross-validation error rates are reported because some 
variant of Approach 1 has been performed. The key principle is that in computing cross-validation 
error rates, within each cross-validation fold only training observations can be used in any aspect of 
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feature selection or model development. Deviations from this principle, even if seemingly innocuous, 
may result in dramatic underestimates of error.  
 
At the end of the feature selection and model building process, the molecular signature must be locked 
down – that is, the precise computational procedure used to convert a new omics sample into a 
prediction of the clinical phenotype must be completely specified. Only then can the molecular 
signature be fairly evaluated on independent data sets, as described next. 
 
Stage 4: Evaluation on independent data sets 
 
Once a promising molecular signature has been identified, its performance needs to be evaluated on 
completely independent patient samples. Unlike cross-validation, wherein the test set is drawn from 
the same population as that of the training set, an independent sample is one that is completely 
separate from the set of samples used for feature selection and model building. In particular, this 
means that the test set is not simply a random split from a large dataset (even if sequestered and not 
used in any training sets). If a molecular signature performs well on a truly independent set of 
samples, then this provides evidence that it will likely generalize to future patient samples. However, 
the amount of evidence for a molecular signature’s performance based on independent data depends 
critically upon specific characteristics of the independent data set.  
 
Lower level of evidence. Good performance on an independent data set collected at the same 
institution using carefully controlled protocols. This provides evidence that the molecular signature 
works well in this particular setting, with these protocols, with the patient profile at this institution, 
etc. However, it may not hold up elsewhere. At the very least, its ability to work in other settings has 
not been demonstrated. 
 
Higher level of evidence. Good performance on multiple independent data sets collected at multiple 
institutions. Success in this setting is the best evidence that a molecular signature will perform well on 
future patient samples. This indicates that the signature is robust to the kinds of things that might 
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change between locations: namely, aspects of the biology of the populations that tend to go to 
particular hospital, sample preparation and measurement techniques used, and so forth.  
 
Evaluation of a molecular signature on fully independent patient samples is the gold standard for 
assessing its performance. Unfortunately, it often is the case that molecular signatures that seem 
promising in the feature selection and model building stage (i.e. that have very low cross-validation 
error rates) exhibit poor performance on independent data.  
 
 
2.3 Disclosing all experimental protocols, data sets, and source code 
 
A key principle of science is that other researchers must be able to reproduce the results. In order for a 
molecular signature to be reproduced, three essential pieces of information are required: 1. The 
experimental and analytical protocols; 2. The raw data; and 3. The source code used to develop the 
signature. We discuss each of these points in turn. 
 
In order for a molecular signature to be fully understood by other researchers, detailed information on 
the experimental protocol, including the patient selection criteria and experimental and analytic 
procedures, must be made available. Without this information, one cannot determine the scientific or 
clinical contexts in which the molecular signature is intended, appropriate, or useful. 
 
Second, in order for a molecular signature to be reproduced, the omics data used in its development, 
as well as the associated metadata and clinical data, must be made available. If the data are not 
released, then it simply is not possible for other research groups to determine whether the molecular 
signature is valid. Since large sample sizes are generally required in order to develop satisfactory 
molecular signatures, it is infeasible due to both time and cost constraints for another group to collect 
their own data set in order to validate the molecular signature. In addition to allowing for independent 
confirmation of the molecular signature (and thereby increasing confidence in its scientific merit), 
releasing data also serves to further science, since then other investigators can use the data for their 
own molecular signature development. This is particularly important because in many applications, no 
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single research group will be able to collect a sufficiently large data set, making meta-analyses of 
large numbers of published datasets highly valuable as an alterative approach. Given the large public 
investment in biomedical science, there is a strong argument for omics data to be made publicly 
available whenever possible, so that it can be leveraged maximally for the public good [74, 75]. 
 
Finally, even if the data are made available, other research groups will not be able re-derive the 
molecular signature based on the same data used for its discovery, and confirm that the signature does 
truly work well on independent data, unless all data processing techniques and all analytical and 
computational methods are made available. Unfortunately, in practice this information often is not 
provided in sufficient detail. For instance, there is a tendency for authors to publish a list of the 
features (e.g. genes) involved in the signature, without the detailed mathematical formulas required to 
understand precisely how the omics measurements are used in order to predict the clinical phenotype 
of interest. This is a major obstacle to progress in the field, as other research groups cannot reproduce 
or validate – much less build upon – research that is not sufficiently reported. Unfortunately, due to 
the complexity of omics data sets and the analyses required to develop molecular signatures, it is 
almost impossible to describe an analysis in sufficient detail that another researcher could exactly 
reproduce those steps. In order to address this problem, the source code used to develop the molecular 
signature should be released. Ideally, this code should encompass all aspects of signature 
development, from processing and normalization of the raw omics data, to feature selection to model 
building to evaluation on an independent data set. 
 
2.4 Using multiple data sets for molecular signature discovery 
 
Thus far, we have described the development of a molecular signature on the basis of a single data set, 
followed by evaluation of the signature on one or more independent data sets. However, in principle, 
multiple data sets can be used for molecular signature discovery. In fact, this can often lead to more 
accurate and more broadly applicable molecular signatures. 
 
When a molecular signature is developed on the basis of a single data set and then tested on an 
independent data set, its performance tends to degrade severely in the independent data set relative to 
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its cross-validation error rate in the data set used for development. This drop in performance can stem 
from heterogeneity between studies due to underlying variance in the biology of the patients studied, 
as well as from technical variations in measurement, normalization, and analysis. That is, a signature 
developed using a single data set may overfit certain aspects of the data set that are not of primary 
scientific interest, leading to poor performance on independent data. This problem can be partially 
overcome by developing the signature on the basis of multiple data sets, collected at different 
institutions and at different time points [76-78]. (However, the primary clinical phenotype of interest, 
such as tumor versus normal, must be balanced between the data sets in order to avoid confounding 
between the data sets and the clinical phenotype.) 
 
2.5 Using multiple data types for molecular signature discovery 
 
Given the complexity of biological systems in general and pathological processes in particular, there 
is an upper limit to how well a molecular signature developed on the basis of a single data type (e.g. 
genome-wide expression on DNA microarrays) can predict disease phenotypes and clinical outcomes. 
Integrating multiple types of omics data may allow for the development of increasingly accurate and 
robust molecular signatures. For example, gene expression data can be combined with copy number 
variation data or DNA sequence data. Successful multi-scale integration of different types of 
biological information is one of the current challenges in systems biology [79, 80]. In Fig. 2.3, we 
provide brief summaries of a few recently published studies [79-86] in which multiple data types were 
used for molecular signature discovery. 
 
A number of methods to combine diverse types of omics data across different measurement platforms 
and laboratories have been proposed [79, 80, 87], in order to more accurately select clinically relevant 
features or to develop better molecular signatures. For example, English and Butte evaluated data 
from 49 obesity-related studies that used different experiment types, including DNA microarrays, 
genome-wide association, proteomics, and RNAi knockdowns [82]. The investigators found that the 
biomolecules reported to be associated with obesity in individual studies had little overlap with 
previously known obesity-related genes. The investigators then determined a gene to be 
obesity-related if 5 or more studies reported the gene to be obesity-related. Using this approach of 
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feature selection, they were able to identify a higher proportion of known obesity related genes than 
from any of the 49 individual studies, and also discovered new genes for which there was compelling 
support of association with obesity [82]. This demonstrated that even straightforward integration of 
multiple omics data types can substantially improve the feature selection process. In a study by Lu et 
al., the investigators integrated data types in order to perform more effective feature selection: they 
identified 475 genes that were differentially expressed between lung adenocarcinoma and normal 
tissue, and that were also located in copy number varying regions [83]. This gene set was used to 
create a predictive model for patient survival, which was then shown to be accurate on three 
independent patient cohorts. Advances in integrating diverse omics data types may lead to a reduction 
in spurious signal caused by technical limitations of individual platforms, and an increased ability to 
identify molecular signatures associated with the underlying mechanistic roles in disease 
pathogenesis.  
 
 
2.6 A network-based approach to molecular signature discovery 
 
The use of network-based approaches is a promising avenue for molecular signature discovery. These 
networks represent a complex web of interactions among diverse components in a cell, and can be 
used to develop more reproducible and accurate molecular signatures by exploiting the underlying 
biology of the system. Network-based approaches extend beyond simple integration of different omics 
data types, and can involve evaluating complex interactions that can vary due to disease or other 
perturbations. 
 
Most statistical methods for feature selection and model building do not take a network-based 
approach: they implicitly assume that the features are independent, or that they are only weakly 
dependent, though this has begun to change in recent years [88-90]. However, in most biological 
contexts, the assumption of independent features is certainly violated. For instance, genes regulated 
by the same set of transcription factors, or genes encoding enzymes for the same metabolic pathway, 
will tend to show correlated expression. Therefore, rather than treating each feature in an omics data 
set individually, it may be preferable to map from the high-dimensional molecular space to a much 
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smaller number of (possibly curated) functional biological networks. Mapping features into functional 
sets reduces dimensionality, increases the statistical power to detect small but coordinated disease 
perturbations, and improves the interpretability of the resulting molecular signatures.  
 
In order to identify features that are associated with a clinical phenotype of interest, features can be 
mapped onto a priori defined and manually curated modules or “pathways”. Gene Set Enrichment 
Analysis (GSEA) [91] is a very widely used approach to investigate pathway-level changes in gene 
expression data, and more recent proposals have also been made. One recently developed approach to 
identifying pathway-based molecular signatures for phenotype classification is the Differential Rank 
Conservation (DIRAC) method [92]. Unlike GSEA or other enrichment methods that usually return 
p-values for gene set enrichment, DIRAC builds a network-based molecular signature that identifies 
robust differences in pathway activity between two disease states.  
 
However, one major caveat to such pathway-based approaches is that a priori defined pathways do 
not fully represent the complexity of the underlying biology, and may not be accurate within the 
particular physiological context. To overcome this limitation, molecular features can be mapped into 
more comprehensive interaction networks, such as protein-protein or protein-DNA interaction 
networks, which can be much more comprehensive and unbiased, as well as disease and context 
specific. Specifically, biological networks can be used as a structured framework to integrate omics 
data for the purpose of molecular signature development. For example, Chuang et al. integrated 
microarray gene expression data with protein-protein interaction networks to identify network-based 
prognostic biomarkers for breast cancer metastasis, and generated novel hypotheses regarding cancer 
progression [84]. The average sub-network activity, defined in this study as a function of expression 
levels of genes that compose the sub-network, was used to predict clinical outcome of breast cancer 
specimens. The network-based markers displayed better predictive accuracy on an independent 
dataset than markers selected without network information. In another study, Nibbe et al. used 
proteins that were differentially expressed between normal and cancer colon tissue from proteomics 
experiments as seeds to identify sub-networks enriched in these differentially expressed proteins from 
the human protein interaction network [93]. Then, the mRNA expression profiles of the components 
of these sub-networks were used as input features to a support vector machine in order to classify 
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colorectal cancer and normal samples.  The prevalence of these networks being perturbed in colon 
cancer was demonstrated by these features alone being sufficient to achieve 90% classification 
accuracy in independent validations.   
 
In the particular case of prion disease, a set of neurodegenerative disorders caused by the misfolding 
of prion proteins in the brain, Hwang et al. analyzed the dynamic network perturbations during the 
onset and progression of disease [86]. In this study, infectious prion proteins were delivered into the 
brains of living mice, and were harbored within the tissue for different time-spans of disease 
progression. At the end of each time-point, gene expression measurements were taken from harvested 
diseased brain tissue, and subsequently mapped onto physical protein interaction networks for 
comparative analysis. Intriguingly, this study showed reproducible perturbations that occurred in core 
networks that could be monitored prior to the manifestation of disease symptoms.  
 
In the work summarized above, thousands of feature measurements for static biological states were 
used to characterize molecular networks. However, a more complete understanding of molecular 
networks requires perturbing the biological system under study in order to understand how the 
network components, as well as the clinical phenotype of interest, are affected by those perturbations. 
For example, stimulating one or more signaling pathways using in vitro cytokine assays can lead to 
different immunologic and metabolic responses in different diagnostic phenotypes [94], such as 
different disease progression levels. In a study by Hale et al. [95], the investigators used a cocktail of 
cytokines and mitogens to stimulate whole blood cells from patients with different stages of systemic 
lupus erythematosus, an autoimmune disease. They then used flow cytometry to measure multiple 
signaling responses at the single-cell level, generating a highly multiplexed view of intracellular 
signaling network activity during disease progression. They found that robust changes in signaling 
protein interactions in response to stimuli were good indicators of disease stage. Therefore, evaluating 
cell response after an activating stimulus may serve as a compelling approach for incorporating 
perturbations into patient classification going forward. 	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2.7 Are my features truly correct? 
 
Given that two molecular signatures seem to perform well on independent data sets, how can we 
decide which is better? If all else is equal, we should prefer the molecular signature for which there is 
a plausible biological mechanism, as such a signature is much more likely to hold up in future patient 
samples as opposed to having overfit the data used in its development. Ideally, if sufficient numbers 
of samples were available, then a molecular signature’s performance on one or many independent data 
sets would be the preferred way of assessing its suitability, regardless of whether or not a mechanism 
for its performance is known. But in reality, sample sizes are limited, and thus a molecular signature 
for which there is a plausible biological mechanism tends to be more convincing than one for which 
no such mechanism is known.  Such biologically motivated signatures can also hold great promise to 
be developed as companion diagnostics for therapies, which may be motivated by the underlying 
mechanism.  Thus, while lack of a known biological mechanism underlying a molecular signature 
certainly does not preclude its use provided that it works well in practice on independent samples, 
mechanistic information can increase our confidence that the signature will hold up to further 
scrutiny.  
 
2.8 Pervasive bias in reported results 
 
Another major challenge in omics-based molecular signature discovery is the prevalence of overly 
optimistic accuracies in reported results. This problem is not unique to omics research but is 
problematic in many data-driven research settings [96]. Such bias can occur for a number of reasons: 
1) research groups tend to report only the best results among many attempted approaches; and 2) only 
positive results are published. Consequently, across the literature there is an overly optimistic view of 
how well molecular signatures perform. This pervasive bias is not necessarily the result of faulty 
science in any particular lab, but rather is a consequence of the way in which science is conducted and 
reported. This is responsible, in part, for the fact that many reported molecular signatures have not 
held up in follow-up studies.  
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2.9 The future of molecular signature discovery 
 
In the future, we envision the development of molecular signatures using large publicly-available 
repositories of data, coupled with unbiased assessment of the successes and failures of these 
signatures. An automated system will integrate all available data for a clinical phenotype of interest, 
identify the most accurate molecular signature using a standard set of computational algorithms, and 
continuously update the signature as new data become available. The candidate molecular signature 
and all relevant performance results (e.g. overall accuracy, sensitivity, and specificity) will be 
reported and tracked over time. Once the molecular signature stabilizes, the system will eventually 
report a final molecular signature for the phenotype of interest. The results obtained from such an 
automated system will be unbiased, in the sense that both positive and negative outcomes (e.g. correct 
and incorrect predictions in the case of a categorical phenotype) will be recorded and reported. By 
integrating huge amounts of publicly available data, such a system will avoid some of the issues 
associated with batch effects and confounding that arise when smaller sample sizes are used for 
molecular signature discovery. Such a system will allow us to develop the most accurate possible 
molecular signatures and assess their performances as objectively and comprehensively as possible.  
 
 
2.10 Conclusions 
 
In this article, we have discussed some of the key considerations and challenges facing the discovery 
of omics-based molecular signatures of clinical phenotypes, such as good experimental design, careful 
data procurement, avoidance of over-fitting, validation on independent data sets, and integration of 
multiple data sets and data types. For guidance to the reader, Figure 2.4 summarizes the key steps in 
molecular signature discovery that were discussed throughout this article. We hope that this 
methodological checklist will aid investigators interested in identifying omics-based molecular 
signatures.  
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Since the emergence of the field of omics-based molecular signature discovery, researchers have 
developed an improved understanding of how to discover (and how not to discover!) such signatures. 
The field is still young, and as time passes, best practices in this area will continue to evolve. 
Currently, the number of validated and useful molecular signatures is disappointingly (but not 
surprisingly) small relative to the number of signatures that have been reported in the literature. 
However, we remain optimistic that as experimental and analytical practices improve, as sample sizes 
increase, and as techniques for data type integration continue to develop, omics-based molecular 
signatures will indeed transform the practice of medicine.  
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2.11 Chapter 2 figures 
	  
 
Figure 2.1 Overview of the discovery and application of molecular signatures from omics data. 
Molecular signatures can be derived from a broad range of omics data types (e.g. DNA sequence, 
mRNA, and protein expression) and can be used to predict various clinical phenotypes (e.g. response 
to therapy, prognosis) for previously unseen patient specimens. 
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Figure 2.2. Two hypothetical scenarios in which (A) hierarchical clustering and (B) principal 
components analysis reveal that covariates other than the clinical outcome of interest have resulted in 
considerable discrepancies between patient populations. Here, batch characteristics and not group 
labels (cancer versus normal clinical specimens) are responsible for most of the observed variation 
among the samples. Such batch effects can arise due to changes in experimental protocols, 
data-processing techniques, or laboratory personnel at any point in the experimental process. 
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Figure 2.3 Combining different types of data across different measurement platforms can lead to more 
accurate molecular signatures for characterizing or predicting clinical phenotypes. Rows and columns 
of the checkered box correspond to data types and published studies, respectively. The collection of 
gray boxes in each column represents the combination of data types used in a particular study. The 
arrows designate the objective of each study. 
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Figure 2.4 Steps for the development of molecular signatures on the basis of omics data.  
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Chapter 3. Relative mRNA levels of Functionally Interacting Proteins are 
Consistent Disease Molecular Signatures 
 
In this chapter, I will describe a new computational tool, interacting Top Scoring Pairs (iTSP) that 
uses the relative mRNA expression reversal of two functionally interacting proteins between 
phenotypes as classifiers. This method extends a family of method that uses relative expression 
reversal of k gene pairs by constraining the gene pairs to be functionally related or physically 
interacting in a protein-protein interaction (PPI) network. I will first review existing Relative 
Expression Analysis (RXA) methods, and then present the iTSP method and comparison to its 
predecessor, the original Top Scoring Pairs (TSP) method.  
 
3.1 Introduction to Relative Expression Analysis family of methods 
 
Many machine learning methods have been applied to gene expression microarray data to identify 
molecular signatures that can accurately predict disease diagnosis, prognosis, and treatment response. 
Such methods often use complex decision rules with many tunable parameters that are not easily 
amenable to biological interpretation. The numerous possible combinations of data normalization 
methods and machine learning methods further complicate the choice of selecting the optimal 
combination. Relative Expression Analysis (RXA) methods uses the relative expression reversal of a 
gene pair between phenotypes (e.g., gene i expression is consistently higher than gene j in class 1, but 
consistently lower than gene j in class 2) as classifiers.  
 
RXA methods have three advantages over other classification methods. First, as ranks of expression 
levels are used in place of expression values, RXA methods are invariant to the choice of all 
normalization methods that do not scramble these ranks. Second, RXA methods use only a small 
number of features and requires little to no parameter tuning. This may facilitate the development of 
inexpensive clinical tests using RT-PCR that only need to measure expression level of a few genes. 
Third, the decision rule is very straightforward to interpret.   
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The foundation of all RXA methods is the original TSP method [97]. Let Pij(Cm)=Pr(Xi>Xj|Y=Cm) be 
the probability of observing Xi>Xj (the expression level of gene i is higher than that of gene j) in class 
Cm. Pij(Cm) is estimated by the frequency of observing Xi>Xj in class Cm. Let Δij= |Pij(C1) - Pij(C2)| be 
the score of each gene pair (i, j), which quantifies the difference in probability of observing Xi>Xj 
between class 1 and class 2. A score of 0 means that the ordering Xi>Xj is equally likely in both 
classes, and the relative ordering of gene pair (i, j) is not informative of class distinction; a score of 1 
means we always observe Xi>Xj in class 1 and never in class 2 (or vice versa), and the relative 
ordering of gene pair (i, j) is highly informative of class distinction. The higher the score, the better 
the gene pair (i, j) can classify class 1 and 2. The original TSP method identifies the gene pair that 
achieves largest Δij as classifier. Although the combinatorial search space is very large, few randomly 
selected gene pairs achieve similar scores as the true TSP [97]. 
 
k-TSP extends TSP by using k disjoint gene pairs, where k is a tunable parameter chosen by 
cross-validation (when k=1, k-TSP is reduced to original TSP) [98]. Decision is based on majority 
voting among k gene pairs. Tan et al compared k-TSP and TSP to commonly used machine learning 
methods such as k-Nearest Neighbor (kNN), Support Vector Machines (SVM), Decision Trees (DT), 
Naïve Bayes (NB), and Prediction Analysis of Microarrays (PAM) in 19 different human cancer data 
sets [98]. k-TSP and TSP perform similar as PAM and SVM. These four methods perform better than 
the remaining methods. Besides similar performance, k-TSP and TSP has the advantage of simple 
decision rules and small number of features (at most 2k) used. Top Scoring Triplet (TST) extends TSP 
by using relative expression reversals among triplet of genes as classifiers [99]. Top Scoring ‘N’ 
(TSN ) extends TSP and TST by using relative expression reversals among n genes (n=2, TSP; n=3, 
TST, n=4, top scoring quadruple, etc) [100].  
 
3.2 interacting Top Scoring Pairs: Putting Biological Constraints on Top Scoring Pairs 
 
Despite its high predictive performance and simplicity, TSP has one major drawback: when it is 
applied to two independent data sets with the same classification endpoint, there is little or no overlap 
in the top 50- or 100-gene pair lists. Low reproducibility in classification methods is not a problem 
specific to TSP. Different partitioning of the same dataset can result in different sets of marker genes 
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for many classification algorithms [101], and the consistency of marker genes across independent data 
sets is even lower [102]. In this chapter, I will describe a method called interacting Top Scoring Pairs 
(iTSP), which integrates functional protein interaction networks (e.g., interactions in the STRING 
database [103]) with transcriptomic data to identify high confidence interacting proteins for which the 
relative expression of the corresponding genes is consistently reversed between phenotypes. iTSP 
retains the desirable features of TSP, including straightforward decision rules, independence of most 
normalization procedures, and a prediction rule based on only two genes. iTSP also achieves a 
predictive performance that is comparable to that of TSP. However, through the integration of 
functional protein interaction networks, iTSP dramatically increases the consistency of gene pair 
selection in comparison to TSP. Moreover, unlike previous network-based classification methods, 
iTSP also accounts for interaction quality and automatically selects high-quality interactions as 
classifiers. Finally, iTSP identifies function protein interactions that can readily serve as a basis for 
generating novel hypotheses about disease processes.  
 
Both TSP and iTSP use a score Δij that quantifies the separability of two phenotypes C1 and C2 based 
on the relative expression level of two genes i and j [97]; see Methods. The score assumes values 
between 0 and 1 and measures how informative the order of expression of the two genes is about the 
true phenotype: Δij = 0 corresponds to no information whileΔij = 1 indicates perfect discrimination.  
The classifier iTSP differs from TSP in two ways. First, iTSP only considers functionally interacting 
gene pairs. Second, in gene pair identification, instead of maximizing Δij  alone, iTSP also takes 
into account  a confidence score S for  the interaction between the gene pair: ∆!"! = 1 − 𝛼 ∗ ∆!" + 𝛼 ∗ 𝑆, 
where α is an adjustable parameter. In the STRING database, the confidence score, S, of interactions 
ranges from 0.15 to 1, which corresponds to the probability of finding the linked proteins within the 
same KEGG pathway [103]. A larger α biases the search for a gene pair towards higher confidence 
interactions, and the parameter is selected with internal cross-validation. In this study, around 400,000 
interactions from the STRING database were considered. To ensure a fair comparison of iTSP and 
TSP, the total number of possible gene pairs for each method was kept the same.  
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3.3 iTSP is comparable in predictive performance to TSP 
We evaluated the predictive performance of iTSP in two ways. We first did 10 repeats of 10-fold 
cross-validation for each of 6 binary classification endpoints on a liver data set consisting of 4 liver 
phenotypes: normal liver (39 samples), chronic hepatitis C (CHC, 36 samples), cirrhosis (CH, 143 
samples), and hepatocellular carcinoma (HCC, 171 samples). Predictive performance was measured 
by the Matthews Correlation Coefficient (MCC), as recommended by the MAQC-II study; MCC 
values range from +1 to −1, with +1 indicating perfect prediction, 0 indicating random prediction and 
−1 indicating perfect inverse prediction[104]. As a control, we performed permutation testing that 
kept the graph fixed, i.e., the number of edges impinging on each node in the PPI unchanged, but 
shuffled the protein (node) labels to generate a random network with equivalent topological 
properties. Thus, each resulting random network had exactly the same node degree distribution as the 
real PPI. The randomized PPI networks were used in iTSP. The average MCCs of iTSP, iTSP with 
randomized PPI, and TSP across 6 binary classification endpoints were 0.755±0.017, 0.724±0.034 
and 0.773±0.022, respectively (Figure 3.1 A).  
As a second and more stringent test of predictive performance, we also did independent validation of 
iTSP and TSP on 6 MAQC classification endpoints, including a positive control (endpoint H) and a 
negative control (endpoint I). For each endpoint, there was an independent training and validation 
data set. We trained on the training data set, evaluated predictive performance on the validation data 
set, and recorded MCC. We then swapped the training and validation data sets and repeated the above 
process. The average MCC of each endpoint is shown in Figure 3.1B. We also plotted the median of 
the 17 best MCCs recorded for each endpoint (“Median of MAQC”), which is used in the MAQC-II 
study as a measure of the inherent predictability of each endpoint[104]. iTSP and TSP had similar 
predictive performance across 6 classification endpoints and the predictive performance depended on 
the inherent predictability of the endpoints. The mean MCCs of iTSP, iTSP with randomized PPI, 
TSP, and “median MAQC” across 5 binary classification endpoints (negative control I is excluded) 
were 0.431, 0.395, 0.412, and 0.441, respectively The MCC for iTSP with randomized PPI was the 
average from 1000 randomized PPI networks. These results show that iTSP performs comparably in 
classification to both TSP and the MAQC-II algorithms. 
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Therefore, in both cross-validation and independent validation, iTSP had comparable predictive 
performance to TSP.  
 
3.4 iTSP significantly increases transcriptomic signature selection consistency  
 
In addition to comparable predictive performance, iTSP significantly increased gene pair selection 
consistency. We used two approaches to assess gene signature consistency. The first approach was 
cross-validation. It has been reported [101] that the particular gene signatures identified within each 
iteration of cross-validation are strongly dependent on data splitting, because i) many genes are 
correlated with the endpoint, ii) the differences in correlation are small and iii) correlation fluctuates 
as different subsets are chosen for training and testing. To evaluate the ability of iTSP to yield 
consistent gene signatures across different training-testing data splitting, we did 10 repeats of 10-fold 
cross-validation. To quantify the consistency of gene pair selection, we calculated the fraction of 
times the same TSP was chosen in two loops within 10-fold cross-validation over the 45 possible 
pairs of loops (C!"! = 45), and averaged the probability across 10 repeats of 10-fold cross-validation. 
Figure 3.2 shows that iTSP had higher reproducibility than TSP in 5 of the 6 liver classification 
endpoints. However, iTSP with real PPI did not always generate more consistent gene pairs than iTSP 
with randomized PPI, which is not surprising since severely limiting the set of gene pairs to choose 
from, whether real or randomized, makes iTSP less susceptible to fluctuations in training data splits 
and score estimation. As iTSP automatically favors high-quality interactions, the median STRING 
score of the 600 interacting gene pairs selected by iTSP (over 10 runs of 10-fold cross-validation for 6 
classification endpoints) is dramtically higher than the median score of all input protein-protein 
interactions to iTSP (0.90 v.s. 0.66, Wilcoxon ranksum test p-value 7.8×10-102). Therefore, the benefit 
of using real functional interactions is that the selected gene pairs are highly likely to participate in the 
same biological pathways, and may point to specific hypotheses about disease perturbation.  
 
The second approach for assessing reproducibility of gene signatures was to use independent data sets 
for the same classification endpoints. In the MAQC study, for the same endpoint, two independent 
data sets (training and validation) were generated from different patient cohorts[104]. We applied 
iTSP and TSP to each independent dataset and compared the overlap of gene signatures learned from 
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the different datasets. Table 3.1 shows the overlap of gene pairs for two independent data sets of 
endpoints D, E, and H using iTSP and TSP, respectively. If there was a strong signal in the microarray 
data and the endpoint was easy to classify, iTSP was dramatically more consistent (i.e., more 
overlapping gene pairs) than TSP. This is the case for endpoint E and H. For endpoint H, which was 
the positive control (sex of multiple myeloma patients), 44 out of the top 50 gene pairs identified by 
iTSP from two independent data sets were the same, while there was no overlapping gene pair 
identified by TSP. When the signal was weaker and the endpoint was harder to classify, such as in 
endpoint D (success of treatment involving chemotherapy followed by surgical resection of a breast 
tumor), the consistency of iTSP decreased, but it was still much higher than that of TSP.  
 
Throughout the analysis, functional protein interactions from the STRING database are used, and 
iTSP automatically favors interactions with high STRING quality scores, and therefore high 
probability of being in the same pathway. It is possible that iTSP achieves higher consistency by 
selecting more redundant gene pairs (i.e. genes that are highly correlated with each other). We 
compared the Pearson correlations of 34 unique gene pairs selected by iTSP in 10 repeats of 10 fold 
cross-validation across 6 liver classification problems with 64 unique gene pairs selected by TSP. The 
correlation is calculated separately for each classification problem (e.g., expression correlation of 
gene pairs selected to classify HCC v.s. normal was calculated based on HCC and normal microarray 
samples). The difference in correlation is not statistically significant: median absolute Pearson 
correlation of 34 iTSP pairs is 0.235, while median absolute Pearson correlation of 64 TSP pairs is 
0.325 (Wilcoxon ranksum test p-value: 0.217). The same results hold if Spearman correlation is used. 
Therefore, even though iTSP favored gene pairs with higher STRING confidence scores and therefore 
higher probability of in the same pathway, the resulting features are no more statistically redundant 
(i.e. correlated) than choosing gene pairs without any functional constraint, as done in TSP.   
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3.5 Favoring high-quality interactions increases transcriptomic signature accuracy and consistency 
 
In addition to considering the level of discrimination Δij, iTSP also accounts for the confidence score 
S of the interaction between the gene pair (i, j). This joint optimization criterion can be viewed as a 
form of regularization that balances predictive performance with biological relevance of the gene pair. 
To evaluate the effects of favoring high-quality interactions, we set the regularization parameter to 
zero and selected gene pairs purely based on the original Δij score. The average MCCs of iTSP and 
iTSP without regularization using 10 repeats of 10-fold cross-validation across 6 binary classification 
endpoints on the liver data set were 0.755 and 0.715, respectively (Wilcoxon ranksum test p-value 
3.3×10-4, Figure 3.3A). In independent validation on the MAQC data set, the average MCCs of iTSP 
and iTSP without regularization across 5 binary classification endpoints were 0.431 and 0.406, 
respectively (Figure 3.3B). Removing regularization also dramatically reduced gene pair selection 
consistency in 10 repeats of 10-fold cross-validation on the liver data set (Figure 3.4). Therefore, we 
showed that favoring high-confidence interactions in iTSP improves both predictive performance and 
the consistency of transcriptomic signature selection. To our knowledge, iTSP is the first 
classification method to explicitly account for the quality of protein interactions, which is important 
because both functional and physical protein interaction networks include many false positive 
interactions.   
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3.6 iTSP identifies protein-protein interactions related to disease processes 
 
As the protein products of gene pairs picked by iTSP functionally interact with each other, we can use 
iTSP results to propose interesting hypotheses about perturbed protein-protein interactions related to 
disease processes. For example, the CYP2C19-GSTP1 gene pair is an accurate classifier between 
chronic hepatitis C and cirrhosis. Both genes are involved in xenobiotic metabolism, and their 
interaction has a confidence score of 0.95 in the STRING database, which is at the highest confidence 
level. CYP2C19 activity is known to be modulated by cirrhosis [105]. The poor metabolizer 
phenotype of the CYP2C19 genotype is more frequent HCV-related cirrhosis [106]. Polymorphisms 
in GSTP1 are known to affect alcoholic [107] and cryptogenic cirrhosis[108]. The relative expression 
reversal of CYP2C19 and GSTP1 (Figure 3.5) may indicate aberrations in xenobiotic metabolism as 
chronic hepatitis C progresses to cirrhosis.  
 
As a comparison, the TSPAN9-RHOG gene pair was often selected by TSP as an accurate classifier 
of CHC v.s. CH. While CYP2C19 and GSTP1 shared two Gene Ontology (GO) annotations, 
GO:0044281 (small molecular metabolism, containing 1300 genes) and GO:0006805 (xenobiotic 
metabolism, containing 140 genes), TSPAN9 and RHOG only shared one very generic GO 
annotation, GO:0016020 (membrane, containing 2240 genes). To systematically quantify whether 
iTSP-selected gene pairs share more specific GO annotations and potentially lead to more specific 
biological hypotheses, we used the Fisher’s Omnibus statistic (Methods, and [109]). A large Fisher’s 
Omnibus statistic means that two genes share a large number of specific GO terms. The median 
Fisher’s Omnibus statistic of 600 gene pairs generated by for iTSP and TSP (including redundant 
gene pairs) in 10 repeats of 10-fold cross-validation for 6 liver classification problems were 6.65 and 
1.37, respectively (Wilcoxon ranksum test p-value 2.2×10-53). As Gene Ontology is among the many 
information sources to calculate interaction confidence scores in the STRING database, the higher 
functional coherence of iTSP-selected gene pairs is partially because of its bias toward high quality 
interactions. The above analysis is therefore not an independent validation of the biological 
significance of iTSP-selected gene pairs, but a demonstration that incorporating functional 
information in classification returns more biologically interesting classifiers than just choosing the 
most accurate classifier.  
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3.7 Conclusion 
 
We developed the interacting Top Scoring Pairs (iTSP) method, which integrates protein interaction 
networks with transcriptomic data to identify functionally interacting proteins for which relative 
expression levels are reversed between phenotypes. While achieving predictive performance 
comparable to TSP, iTSP yields more consistent and biologically meaningful gene signatures.   
 
While previous methods of integrating protein interaction network with transcriptomics data typically 
have focused on identifying sets of nodes for which expression level per se changes between classes 
[110], fewer methods have focused on identifying perturbed protein interactions. iTSP is a novel 
method that identifies functional interactions that are accurate phenotype classifiers and indicative of 
interesting biological processes related to disease. Protein interaction networks are known to include 
many false positive interactions. iTSP improves upon previous network-based classification methods 
by explicitly favoring high-quality interactions with a regularization parameter. This approach is 
applicable to both functional protein interactions in the STRING database or physical protein 
interaction network in the HIPPIE database[111], where quality scores are available.  
 
3.8 Method 
 
Detailed description of iTSP  
 
iTSP scores each functionally interacting gene pair by a combination of Δij and confidence score of 
the interaction: ∆!"! = 1 − 𝛼 ∗ ∆!" + 𝛼 ∗ 𝑆, where S is the interaction confidence score and 𝛼 is the 
regularization parameter. Optimal 𝛼 is determined by 5-fold cross-validation within the first iteration 
of 10-fold cross-validation and used for all 10 iterations. Genes for which expression level were 
below 100 in more than 90% of samples (ignoring class labels) were filtered inside cross-validation 
on training samples before iTSP or TSP were applied. iTSP will be included in future release of 
Adaptive Unified Relative Expression Analyzer (AUREA)[112].  
 
 
 
 
 37 
Fisher’s omnibus procedure 
Fisher’s Omnibus statistic was used to quantify the number and specificity of shared GO annotation 
terms between two genes. A large Fisher’s Omnibus statistic means that two genes share a large 
number of specific GO terms.  
𝐹!" = −2𝑙𝑜𝑔!!,!!∈!! (𝑀!𝑁 ) 
Tm is a GO annotation term. Mt is the number of genes in Tm, and N is the total number of genes with 
GO annotations. Therefore, genes that share many specific terms will have high similarity scores and 
tend to participate in the same biological processes. 
 
Description of data sets used in this study 
The liver data set. We collected 392 transcriptomes from 7 different studies [113-119] from 6 distinct 
labs. This data set consisted of normal liver, chronic hepatitis C (CHC), cirrhotic liver and HCC. We 
downloaded the publicly available raw intensity files of these 392 samples from Gene Expression 
Omnibus and used our own consensus preprocessing pipeline to process the raw data. This pipeline 
went through all three different Affymetrix platforms (U133A, U133 2.0 and U133 plus 2.0), found 
common probe sets across platforms, built a consensus platform, and used the Matlab implementation 
of GCRMA [120] to preprocess all samples together. After this preprocessing step, we had 22,277 
probes in common among the three Affymetrix platforms. Probes that did not map to any known 
genes according to the latest annotation were removed. After this step, we had 20,928 probes. Probes 
were mapped to Entrez gene IDs according to the latest Affymetrix annotations, and if there were 
multiple probes mapping to the same gene, the maximum expression value was used. After this step, 
there were 12725 Entrez gene IDs. ComBat[121] was used to mitigate batch effects arising from 
combining data sets of different sources.  
 
The MAQC data set. The preprocessed MAQC data set was downloaded from[122], and the mapping 
of probe to gene was done as described for the liver data set. 
 
The functional protein-protein interaction network. The human functional protein interaction network 
was extracted from the STRING database version 9.05. Interactions with confidence score above 0.4 
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(STRING database’s threshold for medium confidence level) were used. Ensemble protein IDs were 
mapped to Entrez Gene IDs using Ensemble Biomart. Redundant interactions at the gene level were 
removed, resulting in 401,814 unique functional interactions between 16,560 genes.  
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3.9 Chapter 3 figures and tables 
	  
Figure 3.1 Comparison of predictive performance of iTSP and TSP. A. Predictive performance with a 
liver data set in 10 repeats of 10-fold cross-validation. B. Predictive performance with matched 
MAQC data sets (trained on one set, tested on the other). 
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Figure 3.2 Comparison of gene pair selection consistency between iTSP and TSP. Consistency is 
measured by the probability that the pair of genes selected in two loops of cross-validation are the 
same. 
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Figure 3.3 Comparison of predictive performance of iTSP and iTSP without regularization. A. 
Predictive performance on a liver data set in 10 repeats of 10-fold cross-validation. B. Predictive 
performance on MAQC data sets. 
 
Figure 3.4. Comparison of gene pair selection consistency between iTSP and iTSP without 
regularization. Consistency was measured by the probability that two gene pairs selected by each 
method were the same within 10-fold cross-validation.  
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Figure 3.5. Expression of the GYP2C19-GSTP1 gene pair that accurately classifies chronic hepatitis 
C (CHC, left) and cirrhosis (CH, right). Horizontal lines represent median expression levels of genes 
within a class.  
 
  
Number of overlap gene pairs among top 
Endpoint D Endpoint E Endpoint H 
iTSP TSP iTSP TSP iTSP TSP 
Top 10 0 0 1 0 5 0 
Top 20 0 0 2 0 17 0 
Top 50 5 0 18 1 44 0 
Top 100 15 0 41 1 48 0 
Table 3.1. Consistency of gene pair selection measured by the number of overlapping gene pairs when 
each method was applied to two independent data sets of the same MAQC classification endpoint. 
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Chapter 4. Transcriptional shifts at metabolic branch points reflect 
phenotypic differences 
 
4.1 Identify coordinated transcriptional changes in metabolic network  
 
Metabolism is under extensive transcriptional regulation [200]. Cellular response to genetic and 
environmental perturbations often involves changes in metabolic activities, some of which in the form 
of differential expression of metabolic genes. For example, a recent comprehensive transcriptomic 
comparison of 22 cancer tissues and their cognate normal tissues revealed both common and 
tissue-specific gene expression changes in tumorigenesis [30]. Although gene set approaches such as 
the Gene Set Enrichment Analysis (GSEA) [18] can reveal coordinated transcriptional changes in a 
priori defined gene sets, it cannot account for the topological feature of metabolism: different 
pathways are interconnected. Reporter metabolite analysis [201]. This method defines a 
metabolite-reaction bipartite graph where a metabolite is linked to all reactions that it participates in 
(consumed or produced). Reporter metabolites are metabolites whose associated reactions are more 
significantly differentially expressed than expected by chance, and represent “hot spots” where 
transcriptional regulations occur. This method has been used to identify metabolites affected by 
genetic perturbations in microbes [201] as well as diabetes [202]. 
 
However, reporter metabolite analysis does not consider the directionality of reactions-whether a 
reaction consumes or produces the metabolite. Moreover, it only considers transcriptomic changes of 
reactions directly linked to a metabolite, while it is known that distant reactions can also have an 
impact. Therefore, I developed a new analysis pipeline that considers transcriptional changes at 
metabolic branch points. In particular, the analysis is currently restricted to reactions that consume the 
same metabolite. An example metabolic branch point is the cholesterol 25-hydroxylase and CYP46A1 
reaction pair. At this branch point, cholesterol can either be converted to 25-hydroxycholesterol by 
cholesterol 25-hydroxylase or to 24-hydroxycholesterol by CYP46A1.   
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4.2 Transcriptional shifts at metabolic branch point reaction pairs can distinguish cancer and normal 
tissues 
 
The first question I want to address is, can we distinguish cancer and normal tissue transcriptomes 
using expression profile at metabolic branch points. In this analysis, I used the relative expression 
level of two reactions that consume the same metabolite as classifiers. This is essentially an 
interacting Top Scoring Pairs (iTSP, Chapter 3) approach, where instead of gene pairs, we use 
reaction pairs, and instead of restricting to protein interactions, we restrict to reactions that consume 
the same metabolite. Figure 6.1 showed predictive performance (measured by Mathews Correlation 
Coefficient) across 13 different types of tumor v.s. normal classifications. The average MCC is 0.717 
and accuracy is 0.875.  
 
Table 4.1 listed branch point reaction pairs that show consistent expression shifts between cancer and 
normal tissues across many different types of tissues. Positive score denotes that R1>R2 (i.e., enzyme 
catalyzing reaction 1 is expressed higher than enzyme catalyzing reaction 2) is more frequent in 
cancer than in normal; negative score denotes that R1>R2 is more frequent in normal than in cancer. 
Reaction pairs are sorted by the sum of absolute scores across 13 tumor v.s. normal comparisons.  
 
Catalase (CATm) and glutathione peroxidase (GTHPm) are two different anti-oxidant enzymes that 
convert hydrogen peroxide to water and oxygen. Table 6.1 showed that glutathione peroxidase is 
consistently expressed higher than catalase in tumor tissues, while catalase is consistently expressed 
higher than glutathione peroxidase in normal tissues. Previous experiments suggested that catalase is 
the primary anti-oxidant enzyme when intracellular hydrogen peroxide is low, while glutathione 
peroxidase is preferentially used when hydrogen peroxide concentration is high [203]. It is possible 
that as tumor tissues are subject to higher oxidative stress [204], glutathione peroxidase is preferred 
over catalase. In breast cancer MCF7 cell line, over expression of catalase results in reduced 
expression of glutathione peroxidase and cell proliferation, suggesting that the glutathione peroxidase 
is functionally important in breast cancer [205].  
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4.3 Metabolic heterogeneity at branch points 
 
As discussed in Chapter 1, there is considerable heterogeneity in cancer metabolic profiles. Therefore, 
I analyzed the heterogeneity of reaction expression reversal at metabolic branch points. For each 
reaction pair, an entropy measure is defined as: 
                           H= -log2(p1) - log2(p2), 
where p1 is the frequency of R1>R2, and p2 is the frequency that R2>R1. Entropy is maximized when 
the relative expression level of the two reactions are randome: R1>R2 in 50% samples, and R2>R1 in 
50% samples. Table 4.2 listed branch point reaction pairs that have higher entropy in tumor tissue 
samples than in normal tissue samples: while there is a consistent trend of R1>R2 (or R2>R1) in normal 
tissues, such consistent trend does not exist in the corresponding tumor tissues. This suggests that 
different subsets of tumors have different preference of R1 v.s. R2.  
 
The reaction pair with the greatest entropy difference in tumor v.s. normal across most tissue types is 
GLGNS1 (glycogen synthase) and UDPGP (UDP glucose pyrophosphohydrolase). A recent study 
found that hypoxia induced an early increase in glycogen synthase expression, and glycogen 
utilization is essential to prevent premature senescence [206]. 	  
 
Another interesting branch point with high entropy in tumor is GTHS (glutathione synthase) v.s. 
PRAGSr （ phosphoribosylglycinamide synthase. GTHS is a key step in the biosynthesis of 
glutathione, a key co-factor used by the anti-oxidant enzyme glutathione peroxidase. PRAGSr is a key 
step in inosine-monophosphate (IMP) synthesis, a component of nucleotides. Therefore, this branch 
point represents a balance between coping with oxidative stress and increase proliferation. Recent 
experiments identified that p53 and p21 are key regulators of flux split at GTHS and PRAGSr [207]. 
Under nutrient stress, cancer cells with wild type p53 and p21 can divert more flux via GTHS to 
combat increased oxidative stress, and grow significantly faster than cancer cells with mutant p53 or 
p21, which continue to divert more flux toward IMP synthesis, despite that IMP is a key biomass 
precursor. Higher entropy at this branch point suggests that a subset of tumor samples is limited by 
oxidative stress, while another subset is limited by biomass precursors.  
 
 
 
 46 
The other side of the analysis is branch points with high entropy in normal tissue samples but low 
entropy in tumor tissue samples. These branch points may suggest that compared to normal tissues, 
tumor tissues are “addicted” to a particular reaction at the branch point and therefore show 
consistently higher expression in a particular reaction. Table 4.3  list such branch point reaction 
pairs.  
 
The top reaction pair with low entropy in tumor tissues and high entropy in normal tissues is CYSTA 
(cysteine transaminase) v.s. PPNCL3 (phosphopantothenate-cysteine ligase). Different types of tumor 
tissues all consistently have higher expression level of PPNCL3 than CYSTA. PPNCL3 is a key step 
in Co-enzyme A (CoA) synthesis from pantothenate. As CoA is involved in many biosynthetic 
reactions, this result suggest that tumor tissues consistently favor PPNCL3 over CYSTA because CoA 
for proliferation.  
 
Another reaction pair with low entropy in tumor tissues and high entropy in normal tissues is ACITL 
(ATP citrate lyase) and ACONT (aconitase). Different types of tumor tissues all consistently have 
higher expression level of ACITL than ACONT. ATP citrate lyase is a key step in de novo fatty acid 
synthesis and is reported to be over-expressed in many tumor types. Targeting ACITL has been 
shown to inhibit tumor growth [208], demonstrating the functional implication of this branch point 
expression “addiction”.  
 
4.4 Incorporating global constraints to identify preferred reactions at branch points 
 
Relative metabolic flux split at a metabolic branch point needs not to be determined solely by the 
relative expression level of the corresponding enzymes, as global constraints, especially expression 
levels of upstream and downstream reactions can also have an impact. Therefore, to go beyond just 
using metabolic network topology, I also applied metabolic network functional constraints on flux 
split at metabolic branch points.  
 
1. For each metabolic branch point reaction pair (R1, R2), find the maximum flux through R1 and R2 
without any constraints other than mass balance and thermodynamic. 
 
 
 47 
2. Maximize the agreement between metabolic flux and reaction expression, while forcing reaction R1 
to carry 90% of its maximum flux. The optimal fit is F1, which is the total number of highly expressed 
reactions that carry flux and the lowly expressed reactions that do not carry flux. 
3. Repeat step 2 for reaction R2, get the optimal fit F2 
4. If F1>F2, then R1 is the preferred reaction at this metabolic branch point; if F1<F2, R2 is the 
preferred reaction; if F1==F2, there is no preference.  
This analysis is repeated for each reaction pair in each sample of tumor and normal tissues. Each 
reaction pair will have a score: ∆!= Pr 𝐹! > 𝐹! 𝑇𝑢𝑚𝑜𝑟 − Pr 𝐹! > 𝐹! 𝑁𝑜𝑟𝑚𝑎𝑙  
If ∆! is close to 1, then R1 is consistently preferred over R2 in tumor tissues; if ∆!   is close to -1, R1 
is consistently favored over R2 in normal tissues.  
 
Table 4.4 showed the top 20 reaction pairs with the largest absolute ∆! in pancreatic cancer. The top 
reaction pair adenine phosphoribosyltransferase (ADPT) and nicotinate-nucleotide diphosphorylase 
(NNDPR) is particularly interesting. ADPT is an important reaction in purine nucleotide salvage 
pathway that uses adenine and phosphoribosyl pyrophosphate (PRPP) to form AMP. NNDPR 
catalyzes NAD synthesis from its precursor quinolinic acid. NAD plays a vital role in cancer 
metabolism[209]. Recent experiments found that NNDPR is induced with oxidative stress and is 
associated with poor prognosis in glioma[210]. Another interesting reaction pair is adenylosuccinate 
synthase (ADSS) and argininosuccinate synthase (ARGSS). ADSS is involved in purine synthesis 
while ARGSS is involved in arginine synthesis. Simulation showed that ADSS is consistently 
preferred over ARGSS, which is expected given the importance of purine synthesis in proliferation. 
On the other hand, many types of cancer are known to lack ARGSS and require external arginine 
[211]. Therefore, by applying global functional constraints on flux splits at metabolic branch points, 
biologically meaningful patterns can be identified. 
 
This analysis is complementary to the approach in Chapter 4.2 and 4.3: while 4.2 and 4.3 focus on 
reaction pairs where one reaction is preferred over the other due to relative expression change 
between themselves, 4.4 focus on reaction pairs where one reaction is preferred over the other due to 
global network expression constraints.   
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4.5 Conclusion 
	  
Metabolic changes accompany many physiological (fasting and feeding) and pathological (diabetes 
and cancer) processes. Besides allosteric regulation, many metabolic changes are reflected at the 
transcriptomic level. Expression changes in metabolic affect the fate of key metabolites: 
over-expression of lactate dehydrogenase enables more lactate secretion from pyruvate, while 
over-expression of phosphoglycerate dehydrogenase diverts 3-phosphoglycerate from glycolysis to 
serine and glycine synthesis. This differential expression of metabolic genes results in differential 
allocation of key metabolites to downstream metabolic processes, which may have phenotype level 
consequences. At metabolic branch points, consistently higher expression of reaction i compared to 
reaction j (preferential state) across different samples of one phenotype might imply that reaction i is 
important to the metabolic state of the given phenotype. If this trend is consistently reversed between 
phenotypes (different preferential states), then the reaction pair and the associated metabolite may 
reflect key metabolic differences between the two phenotypes. By incorporating network-level 
expression constraints, additional reaction pairs with different preferential states between phenotypes 
can be identified, even though these reaction pairs may not show expression changes themselves. This 
approach is an important step to use mechanistic knowledge to increase our ability to identify 
perturbed genes and pathways. 
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4.6 Chapter 4 figures and tables 
 
 
Figure 4.1 Predictive performances of metabolic branch point reaction pairs. 
 
 
 
Table 4.1. Metabolic branch point reaction pairs with consistent transcriptional reversals in multiple 
cancer v.s. normal tissue comparisions. Due to space limitation, reaction symbols are used. 
Corresponding reaction names and other information can be found in http://humanmetabolism.org/.  
 
0.0	  
0.1	  
0.2	  
0.3	  
0.4	  
0.5	  
0.6	  
0.7	  
0.8	  
0.9	  
1.0	  
M
at
he
w
s C
or
re
la
tio
n 
C
oe
f. 
Types of cancer 
Reaction 1 Reaction 2 Metabolite Adrenal Astrocytoma Glioblastoma
Oligoden
droglioma Breast Colon Kidney Lung
Head and 
neck Overy Pancreas Prostate Stomach
S4T6g S6T25g Phosphoadenosine phosphosulfate 0.61 0.68 0.57 0.67 0.02 -0.02 0.96 -0.68 0.23 -0.15 0.25 0.03 0.22
ALCD2if ALCD2yf Ethanol -0.61 -0.07 -0.09 0.00 -0.48 -0.60 0.39 -0.63 0.58 -0.55 0.19 -0.15 -0.62
GRTTx IPDDIx Isopentenyl diphosphate 0.30 0.46 0.84 0.32 -0.05 0.53 0.57 0.48 0.20 0.36 -0.03 0.18 0.57
S2T3g S3T2g Phosphoadenosine phosphosulfate -0.18 0.75 0.78 0.71 -0.13 -0.34 -0.66 -0.22 -0.08 -0.44 -0.23 0.00 -0.35
GLCAT3g S2T1g Chondroitin sulfate C precursor 2 0.55 -0.66 -0.22 -0.56 0.39 0.38 0.31 0.53 -0.11 0.27 0.48 0.00 -0.05
ALCD22_D PPDOy D-lactaldehyde 0.00 0.12 0.02 0.06 -0.67 -0.66 0.21 -0.65 0.57 -0.57 0.19 -0.13 -0.65
S3T1g S3T3g Phosphoadenosine phosphosulfate 0.63 0.46 0.41 0.28 -0.26 0.47 0.44 0.23 -0.52 -0.12 0.43 -0.03 -0.18
CDS CPCTDTX CTP -0.03 -0.68 -0.78 -0.71 0.16 -0.12 -0.38 0.17 -0.53 0.36 -0.25 0.10 -0.15
CATm GTHPm Hydrogen peroxide -0.74 0.00 0.02 0.02 -0.49 -0.43 -0.49 -0.53 -0.07 -0.31 -0.43 -0.03 -0.60
ALCD22_L LCADi S-lactaldehyde -0.10 -0.32 -0.22 -0.34 -0.61 -0.52 0.02 -0.40 0.64 -0.09 0.43 0.23 -0.21
ADSS PRASCS Aspartate 0.00 -0.88 -0.88 -0.82 0.08 -0.04 0.28 -0.37 -0.05 0.09 0.14 -0.20 -0.29
ARGSS PRASCS Aspartate -0.45 -0.40 -0.41 -0.41 -0.39 -0.34 -0.55 -0.30 0.21 0.28 0.01 -0.15 0.18
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Table 4.2 Metabolic branch point reaction pairs with high entropy in cancer tissues but low entropy in 
normal tissues. 
 
 
 
Table 4.3 Metabolic branch point reaction pairs with high entropy in normal tissues but low entropy in 
tumor tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction 1 Reaction 2 Metabolite Adrenal Astrocytoma Glioblastoma
Oligoden
droglioma Breast Colon Kidney Lung
Head and 
neck Overy Pancreas Prostate Stomach
GLGNS1 UDPGP UDP-glucose 0.52 0.36 0.69 0.47 0.45 0.41 0.15 0.00 0.03 0.35 0.00 0.17 0.58
DOLPGT1_UerDOLPGT2_UerDolichyl β-D-glucosyl phosphate 0.43 0.62 0.67 0.47 0.42 0.52 0.15 0.02 0.53 0.00 0.03 0.00 0.12
S2T3g S6T3g Phosphoadenosine phosphosulfate 0.55 0.68 0.66 0.69 0.45 0.00 -0.28 0.41 0.28 -0.19 0.38 0.00 0.26
BMTer_U GPIMTer_U Dolichyl D-mannosyl phosphate 0.43 0.32 0.18 0.38 0.41 0.54 0.33 0.36 0.32 0.63 -0.12 -0.35 0.21
GPIMTer_U H3MTer_U Dolichyl D-mannosyl phosphate 0.43 0.32 0.18 0.38 0.41 0.54 0.33 0.36 0.32 0.63 -0.12 -0.35 0.21
GTHS PRAGSr Glycine 0.43 0.27 0.64 0.50 0.48 0.33 0.15 0.21 0.30 -0.16 0.04 -0.06 0.44
GMPS2 NTD10 Xanthosine 5-phosphate 0.15 0.00 0.07 0.00 0.64 0.13 0.59 0.24 0.63 0.68 0.08 0.08 0.28
BPNT2 TYMSULT Phosphoadenosine phosphosulfate 0.37 0.00 0.16 0.10 0.39 0.57 -0.36 0.29 0.27 0.67 0.20 0.00 0.69
BPNT2 ESTSULT Phosphoadenosine phosphosulfate 0.37 0.00 0.16 0.10 0.39 0.57 -0.36 0.29 0.25 0.67 0.20 0.00 0.69
4NPHSULT BPNT2 Phosphoadenosine phosphosulfate 0.37 0.00 0.12 0.10 0.39 0.57 -0.36 0.29 0.26 0.67 0.20 0.00 0.69
Reaction 1 Reaction 2 Metabolite Adrenal Astrocytoma Glioblastoma
Oligoden
droglioma Breast Colon Kidney Lung
Head and 
neck Overy Pancreas Prostate Stomach
CYSTA PPNCL3 Cysteine -0.16 -0.67 -0.55 -0.50 0.00 -0.28 -0.18 0.08 -0.31 0.00 0.00 0.00 -0.38
LCYSTAT PCLYSOX a-ketoglutarate -0.67 0.00 0.00 0.00 0.00 -0.51 -0.65 0.00 -0.41 0.00 0.00 0.12 -0.24
PCLYSOX TYRTA a-ketoglutarate -0.67 0.00 0.00 0.00 0.00 -0.51 -0.65 0.00 -0.41 0.00 0.00 0.12 -0.24
NNMT SRTNMTX S-Adenosyl-L-methionine -0.22 0.00 0.00 0.17 0.00 0.00 -0.46 -0.34 -0.60 0.00 -0.51 0.00 0.00
CORE6GTg N3Tg Tn antigen 0.23 -0.41 -0.23 -0.21 0.00 -0.17 0.00 0.00 0.00 -0.23 -0.21 -0.18 -0.36
S3T3g S4T6g Phosphoadenosine phosphosulfate 0.14 -0.69 -0.40 -0.47 0.00 -0.23 -0.31 0.08 0.39 -0.19 -0.11 0.03 0.12
DOLPMT1_UerH8MTer_U Dolichyl D-mannosyl phosphate 0.00 -0.48 -0.45 -0.42 0.00 -0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00
B3GALT44g GALT2g UDP-galactose 0.00 0.00 0.00 0.00 0.00 -0.64 0.00 0.06 -0.65 -0.34 0.00 0.00 0.00
ASNS1 PRASCS Aspartate 0.23 -0.48 -0.58 -0.42 0.11 0.00 0.15 -0.05 0.06 0.09 -0.35 0.00 -0.33
ACITL ACONT Citrate -0.46 0.27 0.00 0.10 -0.32 -0.17 -0.52 -0.04 -0.48 0.35 -0.42 -0.12 0.26
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Reaction 1 Reaction 2 Pr(F_1>F_2│Tumor) Pr(F_1>F_2│Normal) Delta 
ADPT NNDPR 0.10 0.74 -0.63 
GLUPRT NNDPR 0.10 0.71 -0.61 
ALCD2if ETOHMO 0.92 0.39 0.53 
GLYVESSEC GNMT 0.64 0.21 0.43 
AMETt2m GNMT 0.92 0.50 0.42 
GNMT NORANMT 0.05 0.47 -0.42 
ADSS ARGSS 0.74 0.34 0.40 
ARGSS ASP1DC 0.26 0.66 -0.40 
ARGtm NOS1 0.82 0.42 0.40 
ADMDC GNMT 0.90 0.50 0.40 
ARGSS ASPCTr 0.26 0.63 -0.38 
FPGSm SARDHm 0.72 0.37 0.35 
ALASm GLYATm 0.44 0.11 0.33 
CH25H P45046A1r 0.28 0.61 -0.32 
ARGN NOS1 0.77 0.47 0.30 
TRPHYDRO2 TRPO2 0.00 0.29 -0.29 
P45046A1r P4507A1r 0.79 0.53 0.27 
AKGDm SACCD3m 1.00 0.74 0.26 
CH25H P4507A1r 0.82 0.58 0.24 
DHEASULT PRGNLONESULT 0.23 0.03 0.20 
	   	   	   	   	  Table 4.4. Metabolic branch point reaction pairs with large absolute ∆! in pancreatic cancer.   
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Chapter 5. Reconstruction of genome-scale metabolic models for 126 
human tissues 
 
Human tissues perform diverse metabolic functions. Mapping out these tissue-specific functions in 
genome-scale models will advance our understanding of the metabolic basis of various physiological 
and pathological processes. The global knowledgebase of metabolic functions categorized for the 
human genome (Human Recon1) coupled with abundant high-throughput data now makes possible 
the reconstruction of tissue-specific metabolic models. However, the number of available 
tissue-specific models remains incomplete compared with the large diversity of human tissues.  
 
In Chapter, 4, I report a method called metabolic Context-specificity Assessed by Deterministic 
Reaction Evaluation (mCADRE). mCADRE is able to infer a tissue-specific network based on gene 
expression data and metabolic network topology, along with evaluation of functional capabilities 
during model building.  mCADRE produces models with similar or better functionality and achieves 
dramatic computational speed up over existing methods. Using our method, we reconstructed draft 
genome-scale metabolic models for 126 human tissue and cell types. Among these, there are models 
for 26 tumor tissues along with their normal counterparts, and 30 different brain tissues. We 
performed pathway-level analyses of this large collection of tissue-specific models and identified the 
eicosanoid metabolic pathway, especially reactions catalyzing the production of leukotrienes from 
arachidnoic acid, as potential drug targets that selectively affect tumor tissues.  
 
This large collection of 126 genome-scale draft metabolic models provides a useful resource for 
studying the metabolic basis for a variety of human diseases across many tissues. The functionality of 
the resulting models and the fast computational speed of the mCADRE algorithm make it a useful tool 
to build and update tissue-specific metabolic models. 
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5.1 Background 
 
Metabolic dysfunction has been implicated in a wide variety of human diseases such as obesity, 
diabetes, inborn errors of metabolism, neurodegenerative diseases, and cancer. The recent 
reconstruction of genome-scale models of human metabolism [123, 124] provides an important 
biochemical basis for systems analysis of metabolic related aspects of human physiology and 
pathology [125]. Such systems approaches are critical, as metabolism itself is a molecular 
transformation process where numerous metabolic pathways are inextricably interlinked[126]. 
However, the human body consists of many distinct tissues and cell types, each only expressing a 
fraction of the metabolic genes encoded within the genome [127]. Additional variability arises from 
environmental conditions and external stimuli. None of this variation can be fully accounted for with 
only the generic human metabolic model. Considering the context—e.g., genomic, anatomical, 
environmental, or temporal—under which a subset of the genome-scale biochemical network operates 
is therefore essential to understanding the molecular basis for many human diseases. 
 
The importance of tissue-specific context in disease is evident from distinct metabolic profiles of 
cancers arising from different tissues. For example, it has been experimentally demonstrated that MYC 
oncogene-induced liver tumors show increased glutamine uptake, while MYC-induced lung tumors 
show glutamine secretion [29]. Another study showed that while lactate dehydrogenase A is 
important for breast carcinoma, neuroblastoma, and B-cell tumor cells, it is dispensable for 
MYC-induced lymphomagenesis [128]. Similar results were observed for phosphoglycerate 
dehyrogenease in breast cancer and melanoma [129, 130] versus MYC-induced lymphomagenesis 
[128]. Importantly, cancer metabolism in general also operates in unique environmental and signaling 
contexts compared to normal physiology and metabolic diseases such as obesity and diabetes[126]. 
 
The context in which a metabolic network operates can be viewed at multiple scales, all of which can 
be dependent on one another. The broadest level typically associated with metabolic models is 
genomic context—i.e., the full enzymatic capability encoded in the genome. Since the genome is the 
starting point from which to construct any generic organismal model, we will not consider it further 
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here. A more critical contextual consideration for genome-scale models in higher 
organisms—especially in human tissues—is the subset of metabolic enzymes that are being expressed 
(e.g., represented in the transcriptome) at a given time. The transcriptional regulatory state governs 
which subset of metabolic enzymes and pathways are active, and manifests as either (i) the specific 
expression program for a tissue or cell type; or (ii) the tissue or cellular response to intracellular or 
environmental conditions. The ideal strategy for modeling such contextual differences would be the 
integration of a generic, genome-scale model (e.g., Human Recon 1 [123]) with a detailed, 
context-specific transcriptional regulatory network (TRN), including signaling events that relay cues 
from the cellular microenvironment. However, as these TRNs cannot yet be comprehensively and 
accurately reconstructed and modeled in human cells, recent efforts have turned to employing 
context-specific expression data to create models that are representative of active metabolism in 
specific human tissues and cell types either across a wide range of experimental conditions or under a 
particular condition [31, 131-139]. 
 
For clarity, we will henceforth delineate “tissue-specific” as meaning the representative active 
metabolic network for a tissue (e.g., liver, brain), and “condition-specific” as specific network states 
(e.g., hypoxia, drug treatment) of tissue-specific models. We also note that when higher resolution 
data is available, tissue-specific models can be further discretized into region or cell type specific 
models (e.g., different regions of brain, different neuron subtypes). Tissue-specific models are 
generally more desirable than condition-specific for predictive modeling, because they retain the 
flexibility and redundancy inherent in the metabolic network; specific conditions can subsequently be 
simulated directly by defining model constraints. Generating condition-specific models can still be 
highly useful, especially when coupled with experimental data for testing and validation; methods 
such as GIMME [137]  and iMAT [131] have been used successfully to estimate the metabolic state 
of tissues under particular pathophysiological conditions. While the need for tissue-specific metabolic 
models is strong, the available number remains small. Importantly, significant knowledge and data is 
required to reduce a generic model to a tissue-specific model with enough rigors to allow for different 
condition-specific capabilities. Computational tools that can more rapidly generate tissue models that 
can represent a spectrum of physiological conditions will be highly useful for investigating metabolic 
dysfunctions in various diseases. 
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The Model Building Algorithm (MBA), a current state-of-the-art computational method to build 
tissue-specific metabolic models, has been used to build liver, generic cancer, and two cancer cell line 
metabolic models thus far [31, 135, 136]. The resulting models have been used to predict potential 
drug targets and improve metabolic flux predictions [31, 135, 136]. While a core set of 
high-confidence reactions in MBA is determined based on gene expression or literature evidence, the 
ranking and inclusion of non-core reactions is based on iterative model simulation for many different 
random reaction orderings. Notably, the random sampling in MBA—on the order of 1000 iterations in 
published studies—is limited in its coverage of the large space of possible orderings, potentially 
affecting the accuracy of the tissue-specific model. While this problem is mostly avoided by a 
stringent requirement in MBA for model consistency (i.e., all reactions in the final tissue-specific 
model must be capable of carrying flux), a more deterministic and simulation-independent ranking of 
non-core reactions would serve to dramatically speed up model construction time. 
 
We have developed a method called metabolic Context-specificity Assessed by Deterministic 
Reaction Evaluation (mCADRE) that leverages gene expression evidence, network structure, and 
metabolic function to construct context-specific models in an automated, deterministic, and 
high-throughput fashion. Similar to MBA, mCADRE emphasizes the inclusion of a high-confidence 
core set of reactions from a generic genome-scale model, based on tissue-specific expression 
evidence. Non-core reactions are explicitly ranked according to their own expression evidence as well 
as weighted connectivity to other reactions in the network, and then sequentially removed in the 
inverse order of this ranking. The decision whether to confirm or reject each removal is determined by 
the consequent flux capacity of core reactions, as well as a universal test of metabolic functionality. 
To evaluate the performance of our method, we reconstructed a new liver model and compared results 
to liver models built by MBA: mCADRE was able to achieve similar coverage of high evidence 
reactions, improved metabolic functionality, and dramatic speed up. The deterministic decision 
making in mCADRE, coupled with an automated pipeline of data collection and processing, enables 
researchers to efficiently generate accurate and robust initial models from publicly available 
expression data. 
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As a demonstration of mCADRE’s capabilities, we leveraged data from the Human Gene Expression 
Barcode Project[140] to automatically reconstruct draft genome-scale metabolic models for 126 
human tissues and cell lines, collectively called the Tissue-Specific Encyclopedia of Metabolism 
(TSEM). All 126 metabolic models, mCADRE codes and input data are available at 
http://price.systemsbiology.net/downloads.php.  We identified many amino acid metabolic pathways 
as enriched in 30 brain tissue models in TSEM, which agrees with the known role of amino acids in 
neurotransmitter metabolism. By comparing tumor and normal metabolic networks in TSEM, we also 
identified pathways with known roles in tumor metabolism. In particular, we identified part of the 
eicosanoid metabolic pathway as a potential selective target against tumor tissues. Further analysis of 
metabolic networks in TSEM, especially through integration with regulatory networks and various 
omics data, may offer novel insights of the metabolic aspects of various diseases. 
 
5.2 Method overview and advantageous features of mCADRE 
 
mCADRE builds a tissue-specific model from a generic human metabolic model [123] based 
primarily on gene expression data and metabolic network topology (Figure 5.1). Like MBA, we 
define a core set of reactions that should be present and active (i.e., able to carry flux) in the tissue 
model (we have implemented an adapted version of the checkModelConsistency module described in 
Jerby et al. to identify blocked reactions). The set of core reactions are determined from gene 
expression, and non-core reactions are evaluated and ranked according to a combination of expression 
and connectivity evidence (detail description in Material and Methods). To help ensure the basic 
functionality of the tissue-specific models, mCADRE includes a metabolic function test in the model 
building process. Specifically, the checkModelFunction module tests the ability of the current model 
to produce key metabolites from glucose, based on criteria previously used to universally evaluate 
such models [138]. This list can be customized based on literature evidence or metabolomics data 
(when available) to include tissue-specific metabolites or known capabilities of the tissue or cell type. 
We sequentially prune non-core reactions from the generic model in the determined order, provided 
that removal does not affect fluxes through the core reaction set or production of key metabolites from 
glucose. The former requirement is waived when removing non-core reactions whose associated 
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genes are not expressed in any tissue samples. For each reaction removed from the generic model, all 
resulting inactivated reactions are also removed. 
 
5.2.1 Allowing for a flexible core reaction set increases tissue-specificity of metabolic pathways. 
 
 In addition to the core set of reactions (whose associated genes are expressed in many tissue 
samples), mCADRE defines a negative set of reactions whose genes are not expressed in any tissue 
samples. In this case, when expression evidence strongly suggests that a reaction should not be 
included, we relax the constraint described above to also allow for removal of any consequently 
inactivated core reactions. The non-expressed reaction is removed, along with all reactions that can no 
longer carry flux, only if the ratio of resulting inactivated  core reactions to inactivated non-core 
reactions is smaller than a specified ratio. This parameter governs the sensitivity versus specificity of 
the final tissue model: a lower ratio cutoff leads to inclusion of more reactions with strong positive 
evidence, while a higher cutoff leads to removal of more reactions with strong negative evidence.  It 
is important to note the difference between non-expressed reactions (expression evidence strongly 
suggest the absence of such reactions) and non-gene associated reactions (no expression evidence 
available).  Non-gene associated reactions include spontaneous reactions and reactions catalyzed by 
enzymes not annotated to genes yet. No core reactions are allowed to be removed when mCADRE 
tries to remove non-gene associated reactions.  
 
The utility of allowing for a flexible core can be seen with the bile acid biosynthesis pathway in the 
liver. Although many cell types express several enzymes in the bile acid pathway, the complete 
pathway is present only in the liver [141]. The tissue-specificity of this pathway is also supported by 
microarray data: among 126 tissues, we found that almost all bile acid synthesis reactions have strong 
evidence of activity in the liver, but not in other tissues (Figure 5.2). However, a few reactions in this 
pathway have strong evidence in non-liver tissues (e.g., cerebral cortex). If a "hard" core were to be 
enforced—i.e., requiring all reactions with expression evidence above a threshold to carry flux and 
remain in the tissue model—most reactions in the bile acid synthesis pathway would be included in 
these tissues, even though most reactions in the pathway lack expression evidence. When we allowed 
for a flexible core, only liver and liver cancer models included almost complete bile acid synthesis 
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pathways (85% of pathway reactions present), while most other tissues did not have reactions from 
this pathway.  In contrast, when using a hard core, most models included a majority of bile acid 
reactions (60%~80% of pathway reactions), conflicting with known tissue specificity. For cerebral 
cortex, for example, 70% or 5% of the bile acid synthesis pathway is computed as present when using 
a hard or flexible core, respectively, supporting the importance of including the flexible core in the 
mCADRE approach. This result is achieved when the inactivated core to non-core reaction ratio is set 
at 0.33, and is robust to the ratio (Table 5.1).  
There are 541 and 844 confidently positive (expressed in more than 50% of tissue samples) and 
negative (not expressed in any tissue sample) metabolic reactions in the cerebral cortex, respectively.  
49 confidently negative reactions are needed for the basic functionality of the model (glycolysis, TCA 
cycle, pentose phosphate pathway). To remove all the other 795 confidently negative reactions, 185 
(34.2%) confidently positive reactions have to be removed. On the other hand, to include all 541 
confidently positive reactions, 231 (27.37%) confidently negative reactions have to be included. At 
ratio 0.33, as shown in the table 4.2, 5.18% confidently positive reactions are removed, while 79.62% 
confidently negative reactions are removed. 
 
There are 172 reactions whose associated metabolic genes are not expressed in any cerebral cortex 
microarray samples but still retained in the model. 130 of the 172 reactions’ associated metabolic 
genes have protein-level staining evidence available in the Human Protein Atlas(HPA) [142]. Among 
these 130 reactions, according to gene-reaction mapping, 21, 69, 36, and 4 reactions have negative, 
weak, moderate and strong protein staining evidence, respectively. Therefore, more than 80% of 
confidently negative reactions based on transcriptomic data do have non-negative proteome-level 
evidence. This can either be caused by limitations of the microarray geneexpression measurement, or 
potential effects of post-transcriptional regulation of the corresponding metabolic genes. 
 
 On the other hand, compared with enforcing a hard core reaction set, at ratio 0.33, 28 core reactions 
are removed. Among the 28 reactions, there are 5 UDP-glucuronosyltransferase reactions encoded by 
UTG1A8 and UTG1A10 (gene-to-reaction rule: UTG1A8 or UTG1A10). 
UDP-glucuronosyltransferase reactions occur mainly in the liver and intestines, and neither UTG1A8 
nor UTG1A10 are expressed in brain in general or cerebral cortex in particular[143, 144]. 3 reactions 
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in bile acid synthesis, all associated with the SCP2 (sterol carrier protein 2) are also removed. Sterol 
carrier protein 2 shows negative staining in cerebral cortex neuronal and glial cells in HPA. However, 
according to the input microarray data from the Gene Expression Barcode, all 
UDP-glucuronosyltransferase reactions and reactions associated with sterol carrier protein 2 have high 
expression-based evidence (0.65 and 1, respectively).In these 2 examples, mCADRE correctly 
removed these reactions because many reactions with little expression evidence are needed to 
maintain flux through these reactions, and mCADRE tries to balance strongly positive and negative 
expression evidence.  
 
5.2.2 mCADRE significantly reduces computation time to generate context-specific models 
 The novel reaction ranking scheme based on three criteria (gene expression, network connectivity, 
and literature-supportted reaction confidence level encoded in Human Recon 1) enables mCADRE to 
perform a single optimized iteration to infer a tissue-specific model from the generic human metabolic 
map. In contrast, MBA determines whether to retain non-core reactions through a large number of 
random iterations (typically ~1000) to account for the effects of the order in which reactions are 
removed [135]. The order of reaction removal remains influential in mCADRE—e.g., redundant 
reactions can be removed interchangeably with equal effects on core reactions, but whichever reaction 
is pruned first mandates the retention of the latter. However, mCADRE leverages gene expression, 
topology, and literature evidence to directly determine ordering in a quick deterministic fashion, 
avoiding random iterations. Each iteration in MBA involves Flux Variability Analysis (FVA [145]; 
maximization and minimization of all reactions to calculate flux capacity), which amounts to on the 
order of 10,000 separate optimizations. This computational complexity limits not only the throughput 
of reconstructing metabolic models, but potentially their reproducibility: as the full solution space of 
ordered reaction removals is extremely large, the 1000 permutations sampled by MBA necessarily 
represent only a tiny fraction of all possibilities. The stringent requirement in MBA that final 
tissue-specific models be consistent (i.e., contain no gaps) enforces the inclusion of many 
lower-evidence reactions, and leads to mostly similar models from run to run. Still, even with a 
heuristic speed-up [135] or the efficient fastFVA algorithm [146], one iteration of MBA takes ~10 
hours on a single 2.34 GHz CPU with 4G RAM using the open source glpk solver. The whole MBA 
reconstruction process, with ~1000 iterations, would therefore take on the order of ~10,000 
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CPU-hours. mCADRE dramatically improves the computational speed via deterministic 
evidence-based evaluation of reactions, requiring only ~10 CPU-hours under the same configuration. 
With the IBM Cplex solver (free for academic institutions), the model reconstruction time is further 
reduced to 4 hours. 
 
Manual curation of metabolic models often continues over several iterations of simulation-based 
hypothesis generation, experimental validation, and model refinement to improve quality and 
predictive accuracy. Such iterative curation is also important in computational model reconstruction, 
especially when new and better (i.e., more comprehensive, more sensitive, higher resolution) data 
becomes available. New technologies such as RNA-seq provide unprecedented characterization of the 
transcriptome [147] with a much lower detection limit than microarray. As RNA-seq data become 
available for a variety of tissues and cell types [148], it is important that corresponding models are 
updated to better reflect the metabolic capacity corresponding tissues: metabolic genes expressed at 
low levels may be regarded as not expressed by microarray and excluded from metabolic models. 
Because mCADRE reduces the computational time of model reconstruction almost 1000 fold, it is 
much more convenient to build or update a large collection of tissue-specific models when new data 
are released.  
 
5.3 Coverage-based and functional validation of a mCADRE-constructed liver model 
 
As initial validation of the mCADRE method, we used the algorithm to reconstruct a liver model 
(liverCADRE) and compared it to the liver model in the original MBA publication [135] (henceforth 
referred to as liverMBA), as it is the best characterized MBA-generated tissue model to date. We built 
the liverCADRE model based on 23 normal liver microarray samples. Notably, both mCADRE and 
MBA result in consistent final tissue models, so all liver model reactions examined are able to carry 
flux (Table 5.1). While liverCADRE includes 1763 reactions to the 1826 in liverMBA, the two 
models share 1473 reactions, a significant overlap (Under hypergeometric distribution, the probability 
of observing 1473 or more overlapping reactions is 1.54×10-12, N = 2469, the total number of 
flux-carrying reactions in Recon 1); these overlapping reactions constitute over 80% of all reactions in 
each model, and thus substantial convergence between the approaches, establishing confidence for the 
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quality of models generated with mCADRE. To more directly evaluate the performance of mCADRE 
and MBA for generating new tissue-specific models, we also used MBA to build a model from our 
liver expression training data; liverCADRE exhibited similar or better coverage and increased 
functionality in comparisons with the new MBA model built with the same training data. 
 
5.3.1 mCADRE-constructed liver model improves coverage of highly expressed genes and proteins 
While the two models share most reactions, we chose to further explore the gene-associated reactions 
unique to each model. There are 194 and 169 gene-associated reactions unique to liverCADRE and 
liverMBA, respectively. For each set of reactions, we first examined the coverage of highly expressed 
metabolic genes in an independent data set (test data set), not used in building either liver model and 
based on a different microarray platform than any of the training data used by mCADRE. We assume 
that reactions with strong expression-based validation (whose associated metabolic genes are most 
ubiquitously expressed across new tissue-specific samples) are more likely to be present in the liver. 
The set of gene-associated reactions unique to the mCADRE model have higher expression-based 
validation score than gene-associated reactions unique to liverMBA (Wilcoxon rank sum test p-value: 
6.02×10-9; Figure 5.3A). liverCADRE includes more reactions with strong expression-based 
validation than the MBA model (46% vs. 18%) and fewer reactions with low scores (i.e., poor to no 
gene expression-based validation) than liverMBA (47% vs. 76%; Figure 5.3A). 
 
As mRNA and protein levels are only moderately correlated in mammalian cells [149], we also 
compared coverage of the two liver models at the protein expression level. We collected protein 
staining data from the Human Protein Atlas (HPA) [150] for 560 metabolic genes in Recon 1. Protein 
staining strength is divided into four levels by HPA: strong, moderate, weak, and negative. We 
mapped the HPA data to reactions according to gene-reaction rules, and assigned each reaction a 
score, based on the staining strength of its associated metabolic gene. As shown in Figure 5.3B, 29% 
of gene-associated reactions unique to liverCADRE have strong protein staining support, and 20% 
have negative staining support. In comparison, only 4% of reactions unique to liverMBA have strong 
protein staining support, while 40% have negative protein staining support. Moreover, 
gene-associated reactions unique to liverCADRE collectively have significantly higher scores than 
liverMBA (Wilcoxon rank sum test p-value: 1.25×10-5).  
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5.3.2 mCADRE-based liver model is functionally comparable to the existing liver model  
The liver plays a major role in metabolism and carries out important metabolic functions such as 
gluconeogenesis, triglyceride synthesis, amino acid degradation, and ammonia and ethanol 
detoxification. We investigated the ability of the two liver models to carry out these hepatic metabolic 
functions; the details of each metabolic function simulation are described in Materials and Methods. 
We found that the two models are functionally comparable (Table 5.3), which is expected given that 
they share a large percentage of reactions. Both models can detoxify ammonia and ethanol; both can 
simulate gluconeogenesis from physiologically important substrates such as pyruvate, lactate, alanine 
and glutamine; and both models can degrade most amino acids and produce urea as byproduct. While 
liverMBA can degrade more amino acids and generate glucose from a broader range of glucogenic 
substrates, only liverCADRE is able to synthesize triglyceride from glucose and fatty acids. 
Triglyceride synthesis is a major hepatic function underlying blood glucose and lipid 
homeostasis—the ability to simulate this function in silico enables the investigation of liver metabolic 
network states in normal and pathological conditions such as obesity and fatty liver disease. While 
liverMBA included over 700 reactions manually curated to be active in the liver[135], no such 
curation is done to build liverCADRE.  liverCADRE also outperforms the new MBA liver model 
(liverMBAwang, to distinguish from the original MBA model) built with the same training data in liver 
metabolic function tests.  
 
The liver is also able to regenerate after injury, which involves the synthesis of biomass precursors 
such as nucleotides, amino acids, and lipids. A biomass reaction was added to both models (after 
construction) that accounts for the growth requirement of amino acids, nucleotides, lipids, and other 
metabolites and we tested the ability of the two models to grow in silico in RPMI 1640 tissue culture 
medium conditions. The liverCADRE model was able to simulate growth without further manual 
curation, while liverMBA lacked this capability. Further analysis identified that liverMBA could not 
grow because it contained no reactions in the inosine monophosphate (IMP) pathway, and therefore 
could not produce purines. As de novo purine synthesis primarily occurs in the liver [141], this lack of 
this capability represents a metabolic gap in liverMBA.  Moreover, many membrane phospholipids 
such as phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine and phosphatidylserine are 
derived from triglyceride. As liverMBA cannot produce this metabolite, the production of these 
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glycerophospholipids is consequently blocked. This demonstrated the importance of the metabolic 
function test in mCADRE, as it ensures the basic functionality of the resulting model and may save 
substantial post hoc manual curation.  
 
5.4 mCADRE for high-throughput model generation 
 
After verifying that our new liver model could show similar or better coverage and functionality when 
compared to state-of-the-art models and algorithms, we next took advantage of the automated and 
computationally efficient nature of mCADRE to generate a large collection of tissue and cell type 
specific metabolic models. The Gene Expression Barcode project previously collected, annotated and 
binarized microarray data for 126 human tissues and cell lines on the Affymetrix U133Plus2 platform 
[140]. We used these binarized microarray data sets as input evidence in mCADRE to extract 
individual models from the generic Recon 1, thereby establishing a Tissue-Specific Encyclopedia of 
Metabolism (TSEM). This effort provides the most comprehensive mapping to date of human 
tissue-specific metabolic networks, and for many of the 126 tissues or cell types, this represents the 
first time a genome-scale metabolic model has been built. 
 
5.4.1 Tissue-specific Encyclopedia of Metabolism enables global analysis of human tissues 
	  
The Tissue-Specific Encyclopedia of Metabolism (TSEM) includes 26 tumor tissues and cell lines, 
and 18 of these tumor tissues also have corresponding normal tissue models. It also contains 
metabolic models of 30 different brain tissues, many of which are affected in various neurological 
diseases. A full list of the 126 tissues and the corresponding microarray data can be found at [140] and 
http://rafalab.jhsph.edu/barcode/. All new metabolic models already include several important 
features for in silico simulation of cellular behavior: they have functional central metabolic pathways 
(glycolysis, TCA cycle, pentose phosphate pathway), can synthesize non-essential amino acids and 
nucleotides from glucose, have functional fatty acid synthesis pathway (from acetyl-CoA to 
palmital-CoA), and can synthesize key membrane lipids. These functionalities are a result of the basic 
universal metabolic function test integrated into mCADRE, which can be further customized to reflect 
the specific capabilities of individual tissues and cell types. The latest version of these models, as well 
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as additional models built with latest data (e.g., RNA-seq) can be downloaded from 
http://price.systemsbiology.net/downloads.php 
 
With this comprehensive set of tissue-specific draft metabolic models, we can start to evaluate global 
properties of these networks and their relationship to human metabolism in the body (Figure 5.4). 
Models in the TSEM contain 1161 reactions on average (47% of flux-carrying reactions in Recon 1), 
with most models ranging from 1000 to 1300 reactions (Figure 5.4A). The smallest model is 
neutrophiles, which included 826 reactions. The largest models are liver tumor, normal liver and 
kidney, which included 1550, 1530 and 1416 reactions respectively. This is expected as the liver and 
kidney are among the most metabolically active tissues in the human body. There are 2311 reactions 
that appeared in at least one of the 126 context-specific models, representing 93% of the flux-carrying 
reactions in Recon 1 (Figure 5.4B); 600 reactions appear in at least 90% of the 126 models, and 546 
reactions appear in at most 10% of the models. 
 
5.4.2 Distributions of TSEM model reactions correspond to known features of brain and tumor tissues    
 
We identified pathways that are enriched in brain tissue models—i.e., pathways with more reactions 
present in normal brain tissues than in normal non-brain tissues (Table 5.4). Among the pathways 
most enriched for completeness in brain (compared to normal non-brain tissues) were taurine and 
hypotaurine metabolism, aromatic amino acid biosynthesis, cysteine metabolism, alanine and 
aspartate metabolism , glutamate metabolism, and valine, leucine, and isoleucine metabolism. This 
makes sense, as many amino acids are either neurotransmitters or intermediates in neurotransmitter 
synthesis. The brain is also known to contain higher concentrations of long-chain polyunsaturated 
fatty acids (PUFAs) than most other tissues, and both cerebral endothelium and astrocytes elongate 
and desaturate precursors of the long-chain PUFAs [151, 152]. As such, it is not surprising to see that 
the fatty acid elongation pathway includes significantly more reactions in brain tissues than non-brain 
models. Pathways better enriched in brain tissue models are in agreement with known brain-specific 
metabolic functions, demonstrating the quality of these models.  
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We also identified pathways enriched in the 18 tumor tissues compared to their 17 corresponding 
normal tissues (including two different tumors that arise from the same normal tissue; Table 5.5), 
including folate metabolism, eicosanoid metabolism, fatty acid activation and nucleotide metabolism. 
Folate metabolism is necessary for de novo nucleotide synthesis. The enrichment of reactions for this 
pathway—as well as the nucleotides pathway—in tumor tissue models makes sense because 
nucleotide synthesis is more active in proliferating tumor cells, and many enzymes in nucleotide 
synthesis are classical chemotherapy targets.  
 
Additionally, tumors overexpress fatty-acid synthase (FASN) and undergo significant de novo 
fatty-acid synthesis [153]—FASN has been identified as a drug target in many tumors [154]. Fatty 
acid activation reactions are catalyzed by acyl-CoA synthetase (ACS), which acts downstream of 
FASN and converts long-chain fatty acids to acyl-CoA. Fatty acid activation is a critical step in 
several lipid metabolic pathways, including phospholipid and triacylglycerol biosynthesis. Some 
genes in this pathway (e.g., ACSL4 and  ACSL5) are overexpressed in certain types of cancer and 
inhibition of these genes induced apoptosis in cancer cells [155]. Notably, eicosanoid metabolism is 
the second most tumor-enriched pathway. Eicosanoids, which are biologically active lipids derived 
from arachdonic acid by cyclooxygenase, lipoxygenase, and P450 epoxygenase, have been implicated 
in inflammation and cancer [156]. Biologically active sphingolipids are involved in cancer 
pathogenesis-ceramide functions as a tumor-suppressor lipid, while sphingosine-1-phosphate 
functions as a tumor-promoting lipid[157]. This supports the identification of the sphingolipid 
pathway as enriched in tumor metabolic networks. 
As a comparison, we also calculated the enrichment statistic of these brain and tumor enriched 
pathways using only expression data. Using the gene-reaction-pathway annotation in Recon 1, we 
calculated the average ubiquity score (i.e., how often a metabolic gene is expressed in tissue samples) 
of metabolic genes in a pathway, and compared the average ubiquity scores of the above pathways in 
brain vs. non-brain and tumor vs. normal tissues. As shown in Table S12, only 4 of the 10 
brain-enriched pathways and 1 of the 9 tumor-enriched pathways identified by the model-based 
approach are also found by expression data alone, respectively. This shows the increased signal we 
can get through the model-based approach.  
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We repeated the analysis to identify individual reactions that occur significantly more frequently in 
tumor tissue models than in normal tissues. Interestingly, the top most differentially included 
reactions (Table 5.6) together form part of the eicosanoid metabolism pathway, from arachidonic acid 
to leukotriene A4, C4, D4, E4 and F4 (Figure 5.5). The first two reactions are catalyzed by 
5-lipoxygenase, which is induced by inflammatory stimuli and is often constitutively expressed in 
various cancers [156]. Furthermore, inhibition of 5-lipoxygenase has been shown to reduce cell 
proliferation and angiogenesis [158] and augment the antitumor activity of other drugs [159]. 
Leukotrienes have been implicated in various diseases such as asthma, cardiovascular diseases, and 
cancer [160]. For example, leukotriene C4 and D4 promote angiogenesis [161]; leukotriene D4 also 
promotes intestinal epithelial cell migration [162]. While involvement of genes and metabolites in the 
eicosanoid metabolic pathway has been reported in some cancers, our pathway and reaction level 
analysis revealed the importance of this pathway across a broad range of tumors arising from many 
different tissues.  
 
5.4.3 Comparision of TSEM kidney model with the existing kidney metabolic model  
As a demonstration of the utility of models in TSEM, we compared the TSEM kidney (kidneyTSEM) 
metabolic model with the existing reduced kidney metabolic model (kidneyReduced) from Chang et 
al[133]. While kidneyTS EM is a genome scale metabolic model with 1416 reactions, kidneyReduced 
aims to capture ony the core kidney metabolic phenotype and only included 443 reactions. First, we 
compared the 578 and 34 gene-associated reactions unique to each model that also have protein 
staining evidence (Table 5.7). 554 and 32 of gene-associated reactions unique to each model have 
non-negative protein staining, respectively. Thus, the kidneyTSEM model included much more 
reactions that are active in the kidney. 
 
Chang et al compiled a list of 41 important renal metabolic functions, which consists of the secretion 
and adsorption of metabolites involved in blood pressure. Following Chang et al, we added exchange 
and demand reactions for the 41 metabolites, and maximized the adsorption or secretion of each 
metabolite according to whether it is adsorbed or secreted by the kidney.  
kidneyTSEM is able to achieve 35 of the 41 renal metabolic functions, while kidneyReduced achieved 
all 41 renal metabolic functions. The 6 renal functions that kidneyTSEM failed to achieve includes the 
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secretion of prostaglandin I2, vitamin D, tryptamine, and the absorption of acetate, oxalate, and 
L-carnosine.  
Chang et al also compiled a list of 20 gene deficiencies that are known to cause kidney disorders. 11 
of the 20 genes are in kidneyTSEM model, and all 11 gene deficiencies are predicted by kidneyTESM 
to affect at least one of the 35 renal metabolic functions kidneyTSEM can achieve under normal 
conditions. Thus, the recall rate is 55%, but precision is 100%.  
 
Although not as good as kidneyReduced, kidneyTSEM can simulate most renal metabolic functions 
and have good predictability of genetic perturbations. It is important to note that while reducedKidney 
is based on significant amount of metabolomics  data, transcriptomic data, and most importantly, 
manual literature curation, the reconstruction of kidneyTSEM is fully automated using transcriptomic 
data.  
 
5.5 Comparing mCADRE with the recently published INIT method 
 
During the preparation of this manuscript, a new method (Integrative Network Inference for Tissues, 
INIT) capable of genome scale tissue-specific metabolic network reconstruction was published.  This 
method was used to build genome-scale metabolic networks for 69 human cell types and 16 cancer 
types, collectively referred to as the Human Metabolic Atlas(HMA) [25]. The fundamental strategy of 
mCADRE and INIT is somewhat similar. Both mCADRE and INIT start from a generic human 
metabolic model, and use expression data to infer a tissue-specific sub-network. Both methods require 
that the model should be able to produce certain important metabolites. While mCADRE requires the 
model to produce universally important metabolites from simple precursors like glucose (which may 
overestimate the metabolic capabilities of human cells), INIT allows the model to uptake all 
metabolites to produce these key metabolites (which may underestimate the metabolic capabilities of 
human cells).  
There are certain important differences between the two methods. INIT primarily uses the evidence 
from the Human Protein Atlas (HPA) as input, but can also incorporate gene expression and 
metabolomics data; algorithm parameters (e.g., weights assigned to different level of evidence) are 
also optimized for HPA data [25]. mCADRE can use any data that can quantitatively measure mRNA 
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or protein abundance, but herein primarily uses gene expression microarray data.  Although 
proteome data from HPA provide more direct evidence for the existence of corresponding metabolic 
reactions, current proteomic data is much less comprehensive than transcriptomic data from 
microarray or RNA-seq.  To date, transcriptomic data from public repositories have explored a much 
broader range of human tissue/cell types and pathophysiological conditions: we were able to use 
mCADRE to build 126 human tissue-specific metabolic models based on transcriptomic data from a 
single microarray platform. Additionally, while mCADRE and other model building algorithms 
(MBA, GIMME, iMAT, etc.) are based on the steady state assumption of no net accumulation of 
metabolites, i.e., mass-balance, INIT allows for a small positive net accumulation of metabolites if a 
metabolite is present in a cell type according to metabolomics data.  
 
We validated mCADRE by showing that the mCADRE-built liver model can simulate a wide range of 
liver metabolic functions. An INIT-built liver model was shown to more accurately cover liver 
metabolic gene expression than the manually reconstructed HepatoNet1 [134]. However, it is unclear 
how this better coverage at the gene level will translate to model functionality: while HepatoNet1 was 
tested to be able to simulate a comprehensive set of 442 liver metabolic objectives, no such metabolic 
function simulation was reported for the INIT-built liver model. 
 
We also compared the Tissue-Specific Encyclopedia of Metabolism (TSEM) built by mCADRE and 
the Human Metabolic Atlas built by INIT. Overall, TSEM included 126 models and HMA included 
85 models. HMA included 16 cancer models while TSEM included 26 cancer models; 11 are shared. 
There are 100 and 69 normal tissue/cell types in TSEM and HMA respectively. Overall, the two 
collections shared 21 normal tissues (counting multiple cell types of the same tissue in HMA as one 
single tissue), with 30 unique to HMA and 79 to TSEM. One main difference is the coverage of 
tissues in the brain. While HMA included 8 models covering 3 brain structures (each brain structure 
has 2 or 3 cell-type specific models), TSEM included 30 models covering 30 distinct brain structures. 
Thus, the two collections of tissue-specific metabolic models are largely complimentary, with TSEM 
covering many more tissues. 
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5.6 Conclusion 
 
Large amounts of data have accumulated in public data repositories, characterizing the molecular 
phenotype of a variety of human tissue and cell types across a wide range of pathophysiological states 
[163]. However, the number of available tissue-specific metabolic models, which enable the 
systematic simulation of metabolic functions in normal and disease contexts, remains relatively small. 
To bridge this gap, we have developed a new automated method (metabolic Context specificity 
Assessed by Deterministic Reaction Evaluation, mCADRE) to efficiently build tissue-specific 
metabolic models in a high-throughput manner. From the comparison of brain and non-brain tissue 
models and the comparison of tumor and normal tissue models, it is clear that the pathway-level 
analysis is in agreement with literature. The corresponding models therefore enable further 
exploration of brain-specific metabolic functions and identification of drug targets that specifically 
kill tumor cells with minimal side effects on normal tissues. Combined with automated data 
acquisition and annotation tools [164, 165], mCADRE has the potential to transform large repositories 
of gene expression data into repositories of functional tissue-specific metabolic models. 
 
Importantly, metabolism is under extensive transcriptional regulation [166]. Mutations in transcription 
factors can cause various metabolic diseases [167], and many tumor suppressor genes and oncogenes 
are also transcriptional regulators of metabolism [27]. Combined with methods that automatically 
integrate transcriptional regulatory networks and metabolic networks [85], mCADRE may help to 
systematically identify the metabolic effects of transcription factors perturbations in various tissues. 
Ultimately, we hope to expand the TSEM to include both metabolic and corresponding transcriptional 
regulatory networks for many tissues and cell types. Additionally, metabolic interactions between 
different tissues and cell types play important roles in health and disease [168-171], and there have 
been pioneering studies that used integrated multi-cell type or multi-tissue type models to such 
interactions [138, 139]. The large collection of tissue and cell type specific models in the TSEM may 
facilitate the integrated modeling of metabolic interactions such as those between adipocytes and 
macrophages, different brain tissues, and between tumor and stromal microenvironment.  
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5.7 Materials and Methods 
 
The majority of the automated reconstruction pipeline in mCADRE, including the MAS5 detection 
call, is implemented in Matlab, and the pipeline produces genome-scale draft metabolic models from 
raw expression intensity files. To validate this pipeline, we built a liver model with MAS5 as the 
binarization method and compared it to a liver model constructed with MBA. Aside from the hepatic 
functional testing of liver models, all steps described below were subsequently applied to generate 
context-specific models for 126 different human tissues. Note that the Gene Expression Barcode 
project already used the barcode method to produce binarized transcriptomic data for the 126 tissues, 
so MAS5 was not used in this case. As the barcode binarization tends to be more stringent in calling a 
gene expressed than MAS5 [140], the resulting models may also be smaller than when MAS5 is used.  
 
5.7.1 Gene expression data processing 
 
This new method uses gene expression microarray data as input evidence to prune a generic model 
(e.g., Human Recon 1) to a context-specific subset; the SBML file for Recon 1 was obtained from the 
BiGG database [172] and converted into COBRA Toolbox [173] model structure for subsequent 
analysis. To construct a context-specific metabolic model for the liver, we acquired raw gene 
expression profiles from 23 liver tissue samples from [116, 174-176] and GSE7307 (no citation 
available). All of these studies were identified and annotated by the Gene Expression Barcode Project 
[140]. To approximate the presence or absence of the enzyme and transporter-encoding gene in a 
particular profile, we used the Affymetrix MAS5 detection call to binarize raw microarray data [177]: 
present calls are treated as 1, while marginal and absent calls are treated as 0. Other binarization 
methods, such as the gene expression barcode [140], can also be used. The final binarized expression 
data for all genes g∈G in samples n∈N for a selected context or phenotype is represented as the 
expression matrix X|G|×|N|, where Xg,n = {0,1} represents the presence of gene g in sample n; for our 
liver training data, |G| = 20,283. There are 54,613 probe sets on the Affymetrix U133Plus2 platform 
(excluding quality control probes). Only probes that can uniquely map to a single gene are retained; 
these probes map to 20,283 unique genes. When multiple probes map to the same gene, the maximum 
expression value is used. 
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5.7.2 Assigning evidence scores to reactions 
 
For each reaction r∈R in the generic model, we assign evidence scores (E(r)) to deterministically 
evaluate which reactions to keep or remove when pruning to get a context-specific network. We first 
calculate the expression-based evidence Ex(r) for all reactions to provide an overall ranking and to 
divide reactions into core and non-core sets. Next, the network topology of the generic model is used 
to calculate the connectivity-based evidence Ec(r) for each non-core reaction; this provides a second 
level of evidence when determining the order of reactions to remove during pruning. Finally, if 
expression- and connectivity-based evidence is insufficient to determine the rank of a reaction, 
evidence based on confidence level in the generic model El(r) is considered. 
 
Expression-based evidence 
 
After binarizing the input data, we first quantify how often a gene is expressed across samples of the 
same context; this is the ubiquity score U(g) for each gene g: 
 
U(g) = (1/|N|)∑n∈NXg,n. 
 
This score ranges from 0 (not expressed in any context samples) to 1 (ubiquitously expressed in 
context samples). According to gene-reaction rules, ubiquity scores for metabolic genes are mapped to 
corresponding reactions. That is, the expression-based evidence Ex(r) for reaction r is a function of 
how often its associated genes gr∈Gr are expressed in the selected context, as measured by the 
ubiquity score: 
 
Ex(r) = f(U(gr)), gr∈Gr. 
 
The relationship between the ubiquity scores of Gr and Ex(r), denoted by f, is a composite of the 
Boolean gene-reaction rules defined in the generic model: AND is replaced with MIN, while OR is 
replaced with MAX, following ref [137] (Figure 1A). By definition, the expression-based evidence 
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Ex(r) also ranges from 0 to 1, indicating how likely the reaction is to be present in the selected 
context. The high-confidence core set of reactions is then defined as those with Ex(r) > 0.9 when 
building liverCADRE with MAS5 call binarization, and Ex(r) > 0.5 when building the 126 tissue 
models with the Barcode binarization. Higher cutoff is used for MAS5 call binarized data, as it is less 
stringent than Barcode in calling a gene expressed. Reactions with Ex(r) = 0 are defined as the 
negative reaction set: these reactions have strong evidence of not being active in the tissue context.  
 
Connectivity-based evidence 
 
For non-core reactions, we use network topology to define a secondary metric called 
connectivity-based evidence Ec(r). This score is particularly designed to rank non-gene-associated 
reactions, which account for 40% of all reactions in Recon 1, and by definition, will not be in the core 
because they are not associated with expression data. The connectivity-based evidence for each 
non-core reaction accounts for both the expression-based evidence and connectedness of all adjacent 
reactions (core or non-core). Using the stoichiometric relationships defined in the S matrix, we can 
describe whether any two reactions in the generic model are connected (i.e., share at least one 
metabolite) with the binary adjacency matrix A|R|×|R|. Specifically, Ai,j = {0,1}, where 1 indicates 
reaction i is connected to reaction j. 
 
We consider the outgoing influence I(r) of each reaction as its normalized connectedness to all 
adjacent reactions. That is, for each reaction r, 
 
I(r) = 1/∑j∈R/r (Ar,j). 
 
In this way, r exhibits influence on all other reactions j∈R/r that is inversely proportional to the 
number of reactions to which it is connected. Furthermore, we measure the weighted influence WI(r) = 
Ex(r)×I(r) such that r will exhibit stronger influence on connected reactions if it was found to have 
strong expression-based evidence; reactions with Ex(r) = 0 thus have no weighted influence on 
adjacent reactions. 
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Finally, we define connectivity-based evidence Ec(r) as the net incoming weighted influence to 
reaction r from all other reactions j∈R/r: 
 
Ec(r) = ∑j∈R/r (WI(j) | Ar,j = 1). 
 
If a non-core reaction rj is connected to a highly expressed reaction ri that has few other connections, 
this provides strong support for its inclusion in the context-specific model. Conversely, if a core 
reaction ri is connected to many other reactions, then it is less clear whether any particular connected 
non-core reaction rj is the one that functions in a pathway with ri in the pruned network; as such, the 
resulting connectivity-based evidence for rj will be lower. 
 
Confidence level-based evidence 
 
Confidence scores indicate the level of biological evidence associated with each reaction, as 
determined during manual curation of the generic metabolic model—in this case, Human Recon 1. 
The confidence level evidence El(r) for a reaction ranges from 1 (in silico modeling evidence only) to 
3 (experimental biochemical or genetic evidence); midlevel scores (2) indicate some physiological 
evidence, or experimental support from a related organism, and a score of 0 indicates that the reaction 
was not evaluated. Importantly, these confidence scores represent evidence for the generic model, not 
for the specific context, and thus are considered as a tertiary measure of evidence for non-core 
reactions. 
 
5.7.3 Pruning the generic model 
 
After defining the high-confidence core and ranking all non-core reactions, our algorithm attempts to 
sequentially remove each non-core reaction, starting from those ranked at the bottom (lowest 
evidence). The selected reaction will be removed only if (i) the core set of reaction remains consistent; 
and (ii) removal does not prevent model from producing any key metabolites. Reactions in 
high-confidence core set can only be removed when (i) reactions in the negative reaction set 
(reactions with Ex(r) =0) are needed to enable flux through the high confidence core reactions; (ii) by 
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removing the high confidence core reactions, more non-core reactions (including those in the negative 
reaction set) will be removed. Consistency of the core reaction set is confirmed by calculating the 
maximum and minimum flux for each reaction, and ensuring that at least one is non-zero. As the 
naïve implementation of flux variability analysis (FVA) is extremely slow, we adapted the 
checkModelConsistency module described by Jerby et al. in [135] for optimal performance in 
Matlab—in particular, we included the option to use the efficient fastFVA algorithm[146]. 
 
The list of key metabolites that must be produced from glucose is compiled based on the universal 
metabolic model validation test in[138]. This includes metabolites in glycolysis, TCA cycle, pentose 
phosphate pathway, as well as non-essential amino acids, nucleotides, palmital-CoA, cholesterol, and 
several membrane lipids. Instead of testing the production of all non-essential fatty acids, as in [138], 
we only tested the production of palmital-CoA, which is derived from palmitate, the first fatty acid 
produced in fatty acid synthesis, and the precursor of longer chain fatty acids. Similarly, we only 
tested those membrane lipids that can be derived from glucose and non-essential amino acids. With 
the addition of essential nutrients like choline, these membrane lipids can be transformed to other 
membrane lipids such as phosphatidylcholine and sphingomyelin that cannot be directly synthesized 
from glucose. We only check the production of pyrimidine nucleotides from glucose, as de novo 
pyrimidine synthesis can occur in a variety of tissues [141]. As de novo purine synthesis occurs 
primarily in the liver and other tissues use the salvage pathway [141], we test the ability of all tissues 
to synthesize purine nucleotides from purines bases and 5-phosphoribosyl 1-pyrophophate (PRPP).  
 
5.7.4 Functional test of liver models 
 
In the amino acid degradation test, the model is only allowed to uptake glucose and the amino acid 
being tested; all other organic metabolites are constrained to be efflux only. Transport of inorganic 
compounds (oxygen, carbon dioxide, water, etc.) is unconstrained, except ammonia: as ammonia 
detoxification is an important hepatic function, only ammonia influx is allowed. The simulation 
objective function is to maximize the uptake of the amino acid being tested. Using FVA, if the model 
can allow for finite urea efflux and amino acid influx, the amino acid degradation test is declared as 
passed. 
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Similarly, in the ammonia detoxification test, only glucose uptake is allowed, and the objective is to 
maximize ammonia uptake. This test is passed if the model can allow for finite ammonia influx and 
urea efflux. The ethanol detoxification test is the same as ammonia detoxification test, except that no 
urea efflux is required and ethanol is constrained to be influx. 
 
In the glucogenic test, the model is only allowed to uptake the glucogenic substrate being tested while 
all other organic compounds, including glucose, are constrained to be efflux only. Ammonia is only 
allowed to be influx, and urea is only allowed to be efflux. The simulation objective is to maximize 
glucose secretion. This test is passed if the model can allow for finite glucose efflux. Glucogenic 
substrates tested are the 18 glucogenic amino acids (all 20 amino acid except leucine and lysine, 
which are exclusively ketogenic), lactate, pyruvate, and glycerol.  
In growth simulation, the widely-used RPMI-1640 tissue culture medium was used. The biomass 
equation was adopted from [135]. It consists of amino acids, nucleotides, deoxynucleotides, lipids etc. 
Recon 1 lacks a reaction accounting for the formation of glycogenin, the primer for glycogen 
synthesis, so a sink reaction for glycogenin is added to all the liver models to allow for glycogen 
synthesis.  
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5.8 Chapter 5 figures and tables 
 
 
Figure 5.1 mCADRE method overview. (A) After binarizing context-specific input data, we quantify 
how often a gene is expressed across samples of the same tissue; this is the ubiquity score U(g) for 
each gene g. (B) From ubiquity scores, we calculate the expression-based evidenceEx for each 
gene-associated reaction. Reactions with sufficiently high Ex are defined as the core reaction set and 
are included in the tissue-specific model. To deterministically rank non-core reactions with low to 
moderate expression-based evidence, we introduce a network topology metric to calculate 
connectivity-based evidenceEc. 
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Figure 5.2 Expression-based evidence for the bile acid synthesis pathway across 126 tissues. Red 
squares indicate the average expression-based evidence of all bile acid reactions in the tissue. Normal 
liver and liver cancer tissues, known to synthesize bile acids, are highlighted in blue. 
 
 
Figure 5.3 Coverage-based comparison of mCADRE and MBA liver models. (A) 
Expression-based validation was calculated from an independent microarray data set for reactions 
unique to liverMBA or liverCADRE. (B) Protein staining data from Human Protein Atlas was 
mapped to reactions in each model. 
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Figure 5.4 Number and distribution of reactions in TSEM models. (A) Vertical blue lines indicate 
the number of reactions in each tissue model; green bars show the size distribution across TSEM 
models. (B) Horizontal blue lines indicate the fraction of models in which each Recon 1 reaction is 
included; green bars show the frequency distribution across reactions. 
 
 
Figure 5.5 The leukotriene synthesis pathway formed by the reactions occur significantly more 
often in 17 tumor tissues compared to corresponding normal tissues. 6 reactions are shown; the 
other 7 reactions transport metabolites between cellular compartments. 
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Tuning ratio Model size Pos. removed Neg. removed %Bile reactions present 
0 1194 0.00% 72.63% 70.73% 
0.1 1130 1.11% 75.71% 4.88% 
0.2 1059 2.77% 78.20% 4.88% 
0.25 1037 3.51% 79.03% 4.88% 
0.33 1009 5.18% 79.62% 4.88% 
0.5 909 11.46% 84.24% 4.88% 
1 1216 17.01% 79.50% 9.76% 
2 929 31.79% 93.96% 0.00% 
3 920 32.72% 94.08% 0.00% 
1000 897 34.20% 94.19% 0.00% 
Table 5.1. The effect of tuning parameter that balances the inclusion of high confidence positive 
reactions and the exclusion of high confidence negative reactions.  
 
 
  liverCADRE liverMBA 
Total reactions 1764 1826 
Gene-associated 
reactions 
1192 1167 
Total genes  1264 1333 
Total metabolites 1401 1360 
 
Table 5.2 . Summary of the mCADRE liver model and the original MBA model. 
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Functional tests  liverCADRE liverMBA liverMBAWang 
gluconeogenesis 13/21  19/21  13/21 
Triglycerol synthesis 1/1 0/1  0/1 
Amino acid degradation  19/20  20/20  16/20 
Ammonia detoxification  1/1 1/1  1/1 
Ethanol detoxification   1/1 1/1  1/1 
Nucleotide synthesis  8/8 4/8 0/8 
Table 5.3 Results of hepatic metabolic function simulations 
 
Pathwaysa 
% complete 
in brain 
models 
% complete 
non-brain 
models 
Rank sum 
p-value 
Taurine and hypotaurine metabolism 66% 35% 4.14E-08 
Fatty acid elongation 67% 37% 1.69E-09 
Tyr, Phe, Trp Biosynthesis 77% 56% 4.96E-02 
Salvage Pathway 94% 81% 2.26E-02 
Cysteine Metabolism 50% 37% 3.61E-03 
Alanine and Aspartate Metabolism 73% 61% 2.41E-09 
Glutamate metabolism 86% 76% 1.59E-06 
Butanoate Metabolism 32% 23% 9.34E-03 
Valine, Leucine, and Isoleucine 
Metabolism 
69% 61% 4.00E-02 
Transport, Nuclear 33% 25% 2.05E-11 
aPathways are sorted by difference in percentage of reactions present in brain vs. non-brain tissues. 
Table 5.4 Recon 1 metabolic pathways differentially represented in brain and non-brain normal 
tissues. 
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Pathwaysa 
% complete in tumor 
models 
% complete in normal 
models 
Rank sum 
p-value 
Folate Metabolism 50% 27% 2.8E-03 
Eicosanoid 
Metabolism 
34% 13% 6.6E-04 
Fatty acid activation 91% 81% 1.8E-02 
Tryptophan 
metabolism 
17% 10% 1.2E-02 
Transport, Lysosomal 17% 11% 7.8E-03 
Nucleotides 69% 63% 1.9E-04 
Aminosugar 
Metabolism  
56% 53% 4.8E-02 
Transport, 
Mitochondrial 
25% 23% 3.4E-02 
Sphingolipid 
Metabolism 
13% 12% 3.2E-02 
 
aPathways are sorted by difference in percentage of reactions present in tumor vs. normal tissues.  
Table 5.5. Recon 1 metabolic pathways differentially represented in tumor and normal tissues 
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Reactionsa 
% tumor 
models  
% normal 
models 
Rank sum 
p-value 
ALOX5 72% 6% 8.6E-05 
ALOX52 72% 6% 8.6E-05 
EX_leuktrC4(e) 72% 6% 8.6E-05 
GGT5r 72% 6% 8.6E-05 
GGT6 72% 6% 8.6E-05 
GLUtr 72% 6% 8.6E-05 
GTHRDtr 72% 6% 8.6E-05 
LEUKTRA4tr 72% 6% 8.6E-05 
LEUKTRC4t 72% 6% 8.6E-05 
LEUKTRD4tr 72% 6% 8.6E-05 
LTC4CP 72% 6% 8.6E-05 
LTC4Sr 72% 6% 8.6E-05 
LTD4DP 72% 6% 8.6E-05 
aThese reactions form a pathway that catalyzes the production of leukotrienes from arachidonic acid.  
Table 5.6. Top 13 reactions over-represented in tumor tissue models versus corresponding normal 
tissue models. 
 
  kidneyTSEM kidneyReduced 
  Num.Rxns Percentage Num.Rxns Percentage 
Strong 298 37.11% 12 27.91% 
Moderate 217 27.02% 19 44.19% 
Weak 39 4.86% 1 2.33% 
Negative 24 2.99% 2 4.65% 
No staining 
info 225 28.02% 9 20.93% 
 
Table 5.7 Comparion of protein-level evidence of gene-associated reactions unique to each model  
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Chapter 6. Integrative Reconstruction and Analysis of Genome-Scale 
Metabolic Models of Commonly Used Breast Cancer Cell Lines 
 
6.1 Metabolic heterogeneity in cancer 
 
Reprogramming of cellular metabolism to facilitate proliferation has been recognized as a hallmark of 
cancer [178]. The most prominent metabolic feature of proliferating cancer cells is increased 
consumption of glucose and secretion of lactate even in the presence of oxygen (Warburg effect). 
However, due to differences in tissue of origin, genetic mutation and expression profile of metabolic 
genes, cancer cells exhibit great heterogeneity in metabolic reprogramming, leading to a phenomenon 
dubbed “one hallmark, many faces” [179]. 
 
Tissue and cell type are a major contributor to cancer metabolic heterogeneity. Tissue context can 
affect glycolytic contribution to ATP generation by 2 orders of magnitude, from 0.31% to 64% [180]. 
A recent study found that Myc-driver liver tumor consumes glutamine, while Myc-driver lung tumor 
secretes glutamine [29]. Even for cancer of the same tissue of origin, metabolic profile can still differ 
as a result of genetic mutation or metabolic gene expression. For example, Myc-driver liver tumor 
consumes glutamine while Met-driver liver tumor secretes glutamine. [29]. Metabolic heterogeneity is 
particularly prevalent in breast cancer, where multiple clinically relevant subtypes have been 
established [181]. Luminal subtype of breast cancer cells express glutamine synthetase and are less 
sensitive to glutamine deprivation than basal subtype of breast cancer cells [182]. Most estrogen 
receptor-negative breast cancer cells are dependent on the elevated expression of phosphoglycerate 
dehydrogenase [129]. Loss of the metabolic gene fructose-1,6-bisphosphatase 1 is specifically in 
basal-like breast cancer [183]. This induces glycolysis and results in increased, macromolecule 
biosynthesis, and maintenance of ATP production under hypoxia. 
 
Although a majority of research on cancer metabolism focuses on several central metabolic pathways 
involving glucose and glutamine, other metabolic pathways are increasingly identified as having an 
important role in proliferation. Recent studies found that the production of N-acetylglucosamine via 
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hexoamine biosynthesis pathway is required for glycosylation of proteins involved in cancer cell 
proliferation [184, 185]. S-adenosyl methionine (SAM) is an important co-factor in protein 
methylation and enzymes involved in SAM synthesis and consumption are found to be critical for 
maintenance of stem cell state and tumorigenesis [186, 187]. 
 
6.2 Integration of multiple types of omic data to reconstruct metabolic models 
 
The great complexity in cancer metabolism, in terms of both the heterogeneity and the multitudes of 
pathways involved, necessitates the reconstruction of tissue and cell type specific metabolic models 
that integrates multiple types of functional genomic data to closely represent the specific metabolic 
profile of the given tissue or cell types. Current models of cancer metabolism are often based on gene 
microarray data. In this project, I integrated microarray gene expression data, RNA-seq data, 
proteomic data and metabolite consumption and release data to reconstruct genome-scale metabolic 
models of 3 cell lines commonly used in breast cancer research; MCF7 is the commonly used 
estrogen receptor positive and luminal subtype cell line; MDAMB231 is the commonly used estrogen 
receptor negative and basal substype cell line; MCF10A is the commonly used non-transformed cell 
line.  
 
4 types of data are used in the reconstruction process that complement each other: 
 
Microarray data. Microarray data for each cell line are collected that come from both unperturbed 
and perturbed (hypoxia, drug treatment, etc) conditions to capture the wide metabolic capabilities of 
each cell line. 85, 323, and 129 microarray samples from the Affymetrix U133 Plus 2 platform are 
collected for MCF10A, MCF7 and MDAMB231 respectively. 
  
RNA-seq data. RNA-seq data was collected for each cell line under normal conditions to capture the 
baseline metabolic gene expression[188]. RNA-seq data provides a higher resolution than microarray 
data and also serves as an independent source of evidence about mRNA level evidence. 
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Proteomic data. For MCF10A and MDAMB231, proteomic data was obtained via iquid chro- 
matography tandem mass spectrometry[189, 190]. For MCF7, antibody staining of metabolic proteins 
was obtained from the Human Protein Atlas [142]. 
 
Metabolite consumption and release (CORE) rates. The above 3 data types provide a static picture of 
what genes’ mRNA and protein are detected in the cell lines. The CORE data set measured cellular 
consumption and release rates of glucose, different amino acids, nucleotides, fatty acids, and 
lipids[191], which provides more functional evidence about functional capabilities of the cell line 
specific metabolic network. 
 
A key step in the reconstruction using mCADRE is to define a high confidence positive core reaction 
set and a high confidence negative reaction set. A reaction belongs to positive core reaction set if it 
meets any 2 of the 3 criteria: i) it is detected as “present” by MAS5 algorithm in 25% of microarray 
samples; ii) it is expressed above 2 FPKM in RNA-seq data; iii) it is detected in proteomic data (2 or 
more independent peptides in MCF10A and MDAMB231, at least weak staining in MCF7). This 
ensures that each high confidence core reaction is supported by at least 2 independent data sources. 
Non-core reactions are iteratively ranked by % of microarray samples they are called “present”, 
expression levels in RNA-seq data, connectivity evidence, and literature evidence, and iteratively 
removed from the lowest evidence and highest, as described in Chapter 4.  
 
To ensure cell line specific models have the metabolic capabilities measured in the CORE data, the 
input generic model is fitted to experimentally measured metabolite consumption and release rates. In 
the pruning process, no reactions are removed if the original optimal fit is affected.  
 
After all above steps, mCADRE produced a model with reactions that should be present in each cell 
line. The gene-reaction association rule was then updated with expression evidence to further increase 
cell line specificity.  For example, the gene-reaction rule for reaction i is “gene A or gene B”, which 
means the reaction is present if either A or B is expressed. In a particular cell line, if only gene A is 
expressed, then the rule needs to be updated to avoid false negatives in in silico gene knockout 
simulation. If reaction i is needed for growth, using the original rule, we may come to the false 
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conclusion that knock down of gene A has no effect. As updating gene-reaction rules affects all 
subsequent simulations, only the highly confident negative genes (expressed <10% microarray 
samples AND <0.3 FPKM in RNA-seq data AND not detected in proteomic data) are removed. Note 
that only genes connected by OR are updated: if the gene-reaction rule is “gene A and gene B” , then 
it is not updated. More complex gene-reaction rules are iteratively updated from the most basic parts: 
in  “ (gene A or gene B) and (gene C or gene D) “, the left and right side of “and” is updated.  
 
After running mCADRE to generate a draft model, I manually curated the cell line specific models to 
ensure they do not have futile cycles that enable the production of high energy metabolites (ATP, 
NADH, NADPH, FADH and proton) without any metabolic input. 
 
6.3 Comparison of model prediction and experimental results reveal different types of inconsistency 
 
After manual curation to ensure models pass basic quality checks, in silico single gene deletion 
prediction results were compared with shRNA knockdown data in MCF7 and MDA-MB-231 cell 
lines [192]. In the experiment, cell lines are infected with shRNA libraries and allowed to grow for 
3~4 weeks, and shRNAs that are selectively depleted are chosen as targeting essential genes. Such 
experiments do not directly measure a phenotypic outcome such as growth rate or ATP level. 
 
  
MCF7 MDA-MB-231 
Correct/Total Percentage Correct/Total Percentage 
Sensitivity 9/39 0.23 8/42 0.19 
Specificity 983/1035 0.95 946/982 0.96 
Accuracy 992/1074 0.92 954/1024 0.93 
Table 6.1 Comparison of model predicted lethal genes and lethal genes based on shRNA knockdown.  
 
Table 6.1 showed that although 95% experimentally non-lethal genes are corrected predicted as 
non-lethal (high specificity); only 20% of experimentally lethal genes are correctly predicted as lethal 
(low sensitivity).  
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Systematic comparison between model prediction and experimental result reveal four major sources 
of inconsistency. First, according to model annotation, multiple genes are functionally redundant and 
any one of them can enable the reaction, but only one gene is experimentally lethal. This is the case 
even after gene-reaction association rules are updated to include only expressed genes. For example, 
model predicted that carnitine O-palmitoyltransferase, which transport fatty acid into mitochondria is 
an essential reaction in MCF7. According to model annotation, any one of the three genes, CPT1A, 
CPT1B and CPT1C can catalyze the reaction. Both CPT1A and CPT1B are present in the MCF7 cell 
line, detected at both mRNA and protein level. But only CPT1A is found to be lethal in the shRNA 
knockdown experiment. Another example is the pantothenate kinase reaction (a key step in 
Co-enzyme A synthesis), which is predicted to be an essential reaction by the model. All four 
pantothenate kinase genes (PANK1 to PANK4) are expressed in MCF7 cell line (both mRNA and 
protein level), but only PANK4 is experimentally lethal.  There are three possible explanations for 
this type of inconsistency. shRNA knockdown screen is known to suffer from off-target effects where 
shRNAs target unintended genes. Off-target effects may be exacerbated as sequence similarity of 
functionally redundant genes such as CPT1A and CPT1B is high. Therefore, it is possible that 
shRNAs targeting CPT1A might also have targeted CPT1B. However, this does not explain why 
shRNAs targeting CPT1B have no effect on CPT1A. Another possibility is that genes capable of 
catalyzing the same reaction are not functionally equivalent: the protein encoded by different genes 
may have different kinetic properties (e.g., affinity for substrates, turn over number), which makes 
one isozyme plays a more prominent role than others. Unfortunately, current constrained-based 
modeling approach is not capable of capturing such kinetic differences.  
 
Second, according to model annotation, a reaction is catalyzed by an enzyme complex where multiple 
genes need to be all expressed for the reaction to carry flux, but only one gene is experimentally lethal. 
For example, the ATP synthase reaction is predicted to be an essential reaction. According to model 
annotation, for ATP synthase to be active, all its subunits, encoded by different genes, need to be 
present, and knockdown of any one of the genes will inactivate the enzyme. But only one gene, 
ATP5E is found to be experimentally lethal. Another example is succinate dehydrogenase, where out 
of the four subunits (SDHA to SDHD), only SDHC is experimentally lethal. The same is true for 
NADH dehydrogenase (only NDUFS7 experimentally lethal) and cytochrome oxidase C (only 
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COX5A experimentally lethal). A possible explanation is the off-target effects of shRNA screen, as 
discussed above. Another possibility is that the gene-reaction association in model annotation is 
incorrect.  
 
Third, many experimentally lethal genes are not associated with the synthesis of biomass precursors. 
To model cancer cell growth, biomass composition typically used in simulation studies often includes 
amino acids, nucleotides, fatty acids and lipids. However, many experimentally lethal genes have no 
obvious link to biomass. For example, ATP6V0C is a subunit of vacuolar ATPase that transport 
proton into lysosome and other organelles (organelle acidification), and this process is essential for 
protein sorting, zymogen activation, and receptor-mediated endocytosis. None of these processes are 
reflected in the biomass objective. Even in cancer cells, maximizing growth is not always a primary 
cellular objective and may fail to capture other necessary processes for proliferation, such as coping 
with oxidative stress [193]. Even when an enzyme has clear known role in biosynthetic processes, its 
impact on cell proliferation may not be entirely metabolic: its substrate or product may have functions 
beyond biosynthetic precursors. For example, mitochondrial fumarate hydratase is a key enzyme in 
the TCA cycle, and the TCA cycle supplies crucial biosynthetic intermediates such as acetyl-CoA, 
citrate and a-ketoglutarate. However, fumarate hydratase is actually a tumor suppressor: its 
inactivation leads to elevated intracellular fumarate, which in turn stabilizes HIF (Hypoxia-inducible 
factor)[194]. The transcription factor HIF increases the expression of genes in angiogenesis, cell 
survival, glucose metabolism and invasion. Without experimental knowledge that fumarate can 
stabilize HIF, metabolic model alone cannot capture all the functional consequences of fumarate 
hydratase perturbation. This is further complicated by the fact that the same enzyme encoded by the 
same gene is sometimes distributed in different cellular compartments and performs different 
functions. Fumatrate hydratase has a mitochondrial form and a cytosolic form, encoded by the same 
gene. While the mitochondrial form participate in the TCA cycle and inactivation of mitochondrial 
fumatrate hydratase result in elevated fumarate and stabilization of HIF, the function of the cytosolic 
form has been elusive. Recently, cytosolic fumarate hydratase and its substrate fumarate are critical 
compoents of the DNA damage response[195]. Therefore, fumarate hydratase is not only involved in 
non-metabolic processes, its non-metabolic function is also compartment-specific. In addition to 
functions in a specific biological process such as HIF stabilization or DNA damage response, a 
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metabolic gene can also have a broad impact across many processes. For example, Nicotinamide 
N-methyltransferase (NNMT) consumes methyl units from S-adenosyl methionine to create the stable 
metabolic product 1-methylnicotinamide, decreasing the methylation potential of cancer cells. As a 
result, NNMT-expressing cancer cells have an altered epigenetic state that includes hypomethylated 
histones and other cancer-related proteins combined with heightened expression of protumorigenic 
gene products[187]. The expression level of NNMT is more than 100 fold higher in the ER-negative 
MDA-MB-231 cell line than in the ER-positive MCF7 cell line, suggesting certain potential role of 
NNMT in MDA-MB-231. However, as NNMT decreases methylation potential by creating a stable 
methyl “sink” as opposed to contribute to biosynthetic precursors, MDA-MB-231 metabolic model 
did not predict any impact of NNMT on growth.  
 
Fourth, some metabolic genes have important functions beyond metabolism, and therefore are beyond 
the scope of metabolic models. For example, it has been reported that inhibition of aldolase A, an 
enzyme in glycolysis, has no effect on glycolytic flux or intracellular ATP level, but disrupted 
actin-cytoskeleton dynamics and result in increased multi-nucleation. Cell proliferation can be 
restored by an enzymatically dead aldolase A variant that retain F-actin binding ability, which proved 
that the lethality of aldolase A knockdown is non-metabolic[196]. Another example of a well-known 
enzyme having important non-metabolic function is PKM2. Epidermal growth factor receptor (EGFR) 
activation induces nuclear translocation of PKM2, which binds to phosphorylated β-catenin, leading 
to histione H3 acetylation and cyclin D1 expression. This PKM2-dependent β-catenin transactivation 
is instrumental in EGFR-promoted tumour cell proliferation and brain tumour development[197].  
 
 
6.4 Conclusion  
 
In this project, microarray, RNA-seq, proteomic and metabolic profiling data were integrated to 
reconstruct genome-scale metabolic models for commonly used breast cancer cell lines. These cell 
line specific metabolic models are highly confident representations of the metabolic capabilities of the 
corresponding cell lines: 95% of gene-associated reactions are supported by 2 or more independent 
sources of data, and are able to consume or release glucose, amino acids, lipids and other metabolites 
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at experimentally measured rates. These cell line specific models are therefore an important starting 
point to understand the metabolic states of different breast cancer cell lines.  
 
However, comparison of in silico single gene lethality and experimental results revealed many 
inconsistencies that point to the limitations of current modeling approaches. These inconsistencies are 
valuable to both improve model annotation and the development of new modeling approaches.  
 
First, metabolic genes may have important characteristics that are not captured by current 
constrained-based modeling approach. In an isozyme situation (e.g., CPT1A, CPT1B, CPT1C), 
although each gene product is annotated to be equally capable of catalyzing the same reaction, they 
may either have different metabolic kinetic properties (e.g., affinity for substrates, turnover number, 
susceptibility to product inhibition) that are unknown or not incorporated into model annotation. At a 
even finer level of resolution, it is well known that PKM1 and PKM2, two different splice isoforms of 
the same PKM gene (pyruvate kinase, muscle), have different kinetic properties: PKM1 has 60% 
higher kinase activity than PKM2. This difference has profound phenotypic implications: silencing 
the expression of PKM2 and replacing with PKM1 reverses the Warburg effect (i.e., aerobic 
glycolysis), a metabolic hallmark of cancer [198]. However, in the commonly used BRENDA enzyme 
database [199], most information is organized by Enzyme Committee (EC) number. Therefore, 
CPT1A to CPT1C are annotated to the same EC number; PKLR (pyruvate kinase, liver and RBC) and 
PKM (including PKM1 and PKM2 isoforms) are also annotated to the same EC number. Future 
experiments are needed to examine the metabolic differences between different genes encoding 
different isozymes, and curate a database that records such differences.  
 
Second, it is important to acknowledge that even well studied enzymes (e.g., aldolase A, PKM2) may 
have non-metabolic functions, and sometimes it is these non-metabolic roles that are more important. 
Therefore, metabolic model is only part of the toolkit to study biological complexity. 
 
Third, more realistic biological objective functions in addition to maximizing growth are needed to 
capture the important functions of many metabolic genes. There are several approaches to achieve this. 
One is to include the production of metabolites with known roles in non-metabolic processes in the 
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objective function. S-adenosylmethionine (SAM) is an important methyl group donor in many 
methylation reactions that affect cellular epigenetic state, and the ratio of between SAM and 
S-adenosylhomocysteine (SAH, product after methyl donation) is a measure of cellular methylation 
potential. Acetyl-CoA affects histone acetylation and global gene expression. α-ketoglutarate affects 
DNA methylation. Hexoamines modifies nutrient transporters and growth factor receptors and 
regulate their translocation. Fatty acids such as myristate, palmitate, farnesyl and geranylgeranyl 
groups are important substrates in protein modification and affect protein trafficking. Fumarate 
hydratase stabilizes HIF and increases the expression of pro-survival genes. Including these 
metabolites in the objective function may enable the identification of reactions that affect cell 
proliferation via influence on the production and consumption of these metabolites.  
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Chapter 7. Conclusion 
	  
Technical advances have dramatically increased the ability to measure biological systems at 
increasingly greater levels of resolution, from whole tissues to single cells and subcellular organelle; 
and more comprehensively from genome, transcriptome, proteome and metabolome. For each 
biological sample, millions of heterogeneous multi-omic data points are measured. For common 
diseases, especially cancer, large consortia such as The Cancer Genome Atlas, have gathered 
multi-omic data from hundreds of patients. The key task is to translation this “big data” into 
knowledge that help disease diagnosis and increase our understanding of how biological networks 
operate.  
 
Many statistical approaches have been used to uncover meaningful patterns from large amount of 
biological data. Statistical tests such as t-test or Wilcoxon ranksum test are used to find genes with 
different mRNA level between conditions. Logistic regression is used to identify single nucleotide 
polymorphisms (SNPs) that are associated with phenotypic traits. Supervised approaches such as 
support vector machines (SVM), k-nearest neighbors (kNN) are used to find accurate classifiers that 
distinguish phenotypes. Unsupervised approaches such as clustering are used to uncover clinically 
meaningful subtypes of diseases previously regarded as homogeneous. These tools are unbiased, as 
they make no a priori assumption about what biological features are more important than others. In 
addition, they often assume different biological features are independent. These statistical approaches 
are important tools when we know little about the given biological problem, or when the primary 
objective is to find the most informative features.  
 
However, prior knowledge is a powerful resource to both account for the relations between biological 
features (pathways, protein-protein interactions, transcription factor-target genes) and reduce the 
search space to biological features that have known biological functions. Successful incorporation of 
prior knowledge include gene set enrichment analysis (GSEA) that identify coordinated expression 
change in a priori defined pathways, or pathway-level genome wide association study (pathway 
GWAS) that identify a group of functionally related genes jointly associated with a trait of interest.  
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The central theme of my thesis research was to use prior knowledge as biological constraints in the 
analysis of disease omic data (Figure 7.1). In Chapter 3, interacting Top Scoring Pairs (iTSP) 
improves upon previous methods by restricting searches to gene pairs with known functional 
relations. In Chapter 4.2 and 4.3, a more mechanistic constraint is applied to identify interesting 
expression patterns of reaction pairs that consume the same metabolite. Unlike protein-protein 
interaction networks (used by iTSP in Chapter 3) that suffer from high false positives, or signaling 
networks that are very incomplete, metabolic networks are arguably the most well characterized 
biological networks. This enables more mechanistic interpretation of omic data analysis. For example, 
if the protein products of two genes interact, relative expression changes between the two genes may 
not always have straightforward interpretation. On the other hand, if there is a relative expression 
change between two reactions consuming the same metabolite, it is reasonable to assume that this 
change may affect the allocation of the given metabolite to different utilization pathways.  
 
Many existing methods test the enrichment of differentially expressed genes in a priori defined gene 
sets: GSEA typically use biological pathways, while reporter metabolite analysis use genes linked to 
the same metabolite. Although they facilitate the interpretation of statistical analysis results, they do 
not account for the mechanistic link between biological features. For example, expression aberration 
or deleterious mutation in any single subunit of an enzyme complex is expected to have similar 
phenotypic consequences. Similarly, such aberrations along a contiguous chain of metabolic reactions 
are also expected to have similar effects: SNPs in different genes encoding enzymes in heme 
biosynthesis pathways all result in porphyria. Based on such mechanistic links, in a hypothetical 
scenario to “rediscover” causal pathways linked to porphyria, heme biosynthesis pathway can be 
identified without resorting to statistical enrichment. To exploit such mechanistic links on a network 
level, in Chapter 4.4, a new analysis approach identified the preferential allocation of metabolites at 
metabolic branch points by considering the constraints imposed by the gene expression states of all 
reactions in the network, not just the reaction pairs at the branch point. This analysis is an important 
step in the development of “mechanistic classifiers”, where different phenotypes are distinguished by 
their network states. The network state is constrained by both the expression, phosphorylation or 
methylation status its components and the mechanistic links between its components based on prior 
knowledge.  
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The other theme of my research is the contextualization and refinement of prior knowledge by omic 
data (Figure 7.2). The generic human metabolic network is reconstructed from extensive literature 
curation and represents the union of known metabolic capabilities of all human tissues and cell types. 
In Chapter 5, I developed mCADRE to contextualize the generic human metabolic network using 
transcriptomic, proteomic and metabolomic data of a given tissue. These tissue- and cell-type-specific 
models can then be compared with context-specific perturbation data (e.g. shRNA knockdown, 
enzyme inhibition) to reveal knowledge gaps in our current understanding of human metabolism.  
 
Taken together, the main achievement of my dissertation is the development of various computational 
pipelines that integrates statistical and mechanistic modeling approaches. These comoputational 
methods incorporate prior knowledge into disease omic data analysis and contextualize prior 
knowledge with omic data. Large consortia continue to generate and process large omic data sets (e.g. 
The Cancer Genome Atlas), as well as to curate and catalogue prior knowledge (e.g., the Human 
Recon 2). The computational tools developed in my thesis have substantial promise to harness the 
power of omic data and prior knowledge to generate new biological hypotheses and insights. 	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7.1 Chapter 7 figures 
	  
Figure 7.1. Successively more mechanistic biological constraints are applied to disease omic data 
analysis to improve diagnosis and generate new hypotheses.  
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Figure 7.2. Contextualization and refinement of prior knowledge (e.g. metabolic networks) using 
omic data. Tissue-specific metabolic models are inferred from generic human metabolic network 
based on various omic data evidence. These models are further refined by comparison with tissue and 
cell-line-specific perturbation data (e.g., shRNA knockdown). 
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